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Science is what we understand well enough to explain to a computer. Art is everything
else we do.
We should continually be striving to transform every art into a science: in the process,







Sudden cardiac death, caused by ventricular fibrillation, is a leading cause of mortality.
To date, the only treatment is the delivery of a high-energy electrical shock through
the heart, either externally or through implanted devices. Although potentially life-
saving, these shocks can be painful and traumatic for patients, especially when delivered
due to diagnostic errors or device malfunctions. A promising new method to terminate
ventricular fibrillation more gently is Low Energy Antifibrillation Pacing (LEAP). LEAP
applies a series of pulses at low electric field strengths, thereby exciting the heart muscle
locally at many different locations and synchronizing the tissue. In this work I show
that this excitation takes place at the cardiac vasculature and that LEAP leads to
substantial energy reductions. With the use of a micro-CT scanner, I obtained three-
dimensional data of cardiac vasculature of dogs and pigs and quantified the vessel sizes
with a custom-developed algorithm. I found that the size distribution of the coronary
vasculature follows a power law that can be transformed into a prediction of the dynamic
behavior of cardiac tissue. To assess the efficiency of LEAP in clinically relevant settings,
I performed in vivo and ex vivo experiments on porcine and canine hearts. On average,
the defibrillation energy using LEAP could be decreased by up to 70% compared to the
respective single shock energy. Pacing slower than the dominant fibrillatory frequency
was more efficient than faster pacing, which supports the hypothesis that direct access
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The history of modern physics started in the 16th and 17th century with the discovery
and mathematically exact description of natural phenomena on the largest length scales
imaginable at that time: Earth, the Moon, the Sun and the other planets in our solar
system. The classical mechanical laws by Kepler, Galileo and Newton describing those
systems remained valid for hundreds of years and most scientific discoveries were con-
cerned with macroscopic systems. Mechanics, thermodynamics and electricity could be
described easily on everyday scales. The scientific (or at least the physical) world view
changed again at the beginning of the 20th century, with the revolutionary insight that
it was not possible within the known natural laws to take the limit towards very large
or very small systems. One can say that the most important physical advancements in
most of the 20th century were on the (sub)atomic and the cosmological scale.
But in the last decades, a new class of problems has received the focus: complex sys-
tems on the boundary of statistical physics, biology, information theory, socio-economic
sciences and nonlinear dynamics. They tend to happen on mesoscopic scales and show
emergent behavior (both phrases have become too much buzzwords to be of much use
anymore) and so far proved very resilient against complete analytical descriptions. In-
cidentally this probably also is as accurate a definition of “complex systems” as one
can get. Bar-Yam [1] gives a very similar definition: “the complexity of a system is
the amount of information needed in order to describe it.” From a physicist’s point of
view, also biology and medicine are complex systems and questions arising in these fields
should be tackled with physical methods for thorough understanding.
One of the leading causes of mortality worldwide is sudden cardiac death (SCD). In
Europe alone, an estimated 500 000 people per year [2] die because their heart “stops
beating”. Globally in the industrialized countries, the incidence of SCD is approximately
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40–100 cases per 100 000 inhabitants and year [2–4]1. It turns out the reason for ventric-
ular fibrillation, the medical condition underlying SCD is best understood by describing
the heart as an excitable medium, a prime example of complex systems. With this
description one can gain insight into the underlying mechanisms and develop fundamen-
tally better treatments. In the following chapters, I will show how heterogeneities in the
heart act with the surroundings tissue when synchronizing it with low energy electric
stimuli and that low-energy approaches increase the defibrillation efficiency by 70%.
1.1 Excitable Media
Many active systems far from equilibrium can be described as excitable media. In chap-
ter 2, I show how many biological and chemical systems and also cellular automata
share the same mechanism of activation, refractory periods and communication which is
common to this class of systems. For many systems, modeling as an excitable medium
offers a practical abstraction.
1.1.1 The Heart and Arrhythmias
The heart and especially the cardiac muscle is a classical example for an excitable
medium since excitation may spread over the whole muscle once activated in one place.
There are many mathematical models [7] to describe its behavior through reaction-
diffusion equations, ranging from just two local variables (for example in the manner
of [8] or [9]) to models trying to model cellular dynamics to much higher degrees of
accuracy (e.g. [10] with more than 40 variables).
Given the complexity of the underlying dynamics, it comes as no surprise that the heart
supports several spatio-temporal excitation patterns. The sinus rhythm during normal
heart beat is just one example, but there is also a whole zoo of arrhythmias, some of
which are self-sustaining and potentially lethal.
1.1.2 Classical Defibrillation and a LEAP Forward
The classical method to terminate arrhythmias, if local stimulation with low voltages is
ineffective, is to deliver large electrical shocks across the heart. This effectively resets
all cells of the heart into a common state, thereby eliminating spatial activity inhomo-
geneities. Starting with the next heart beat, the normal heart rhythm can take over
1For SCD numbers in e.g. India, a prototypical newly industrialized country, see [5, 6].
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again. Patients with a disposition to life-threatening arrhythmias may obtain implanted
defibrillators to automatically deliver these shocks if required.
Because the defibrillation shocks may be potentially harmful to the tissue and can be
perceived as very painful, better arrhythmia-terminating methods are required. In chap-
ter 3, I present an approach towards more gentle defibrillation, Low-Energy Antifibrilla-
tion Pacing (LEAP), where many small shocks reset the cardiac muscle locally at many
places.
1.2 Connecting Structure and Function
1.2.1 LEAP and Structure
The mechanism by which LEAP causes synchronization locally at many locations de-
pends on structural heterogeneities in the tissue. Ventricular tachycardia and fibrillation,
the most dangerous kinds of arrhythmias are also influenced by the heart’s internal struc-
tures, which suggests an intimate connection between the mechanisms of the arrhythmias
and LEAP.
1.2.2 Cardiac Vasculature
The most ubiquitous structuring component in the heart is the vasculature, which makes
it an ideal candidate for LEAP’s mechanism. I show in chapter 4 and 5 that the blood
vessels’ size distribution follows a power law and that this distribution can be linked
conclusively to the effects of low electric fields on heart tissue as demonstrated in optical
mapping experiments.
1.3 Classical and Advanced Defibrillation on Real Hearts
Although numerical models can predict many properties of (de)fibrillation, complete and
accurate simulation of a whole heart and the effect of electric fields is not possible yet.
Until then and to verify numerical results, experimental tests are necessary and provide
new insights.
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1.3.1 In Vivo and Ex Vivo Experiments
Testing defibrillation on whole hearts or regular tissue is closer to eventual application
in humans than experiments on in vitro cell cultures. In the chapters 6 and 7, I describe
in vivo and ex vivo experiments to evaluate the implementation of LEAP in clinically
relevant environments. While in vivo experiments are as close to the human organism as
possible in pre-clinical studies, ex vivo setups provide for a more controlled environment.
Combined they maximize the time of experiment for each heart.
1.3.2 Energy Reduction and LEAP Parameters
Although the experimental defibrillator devices used in the experiments are far from
being reduced to a size that can be implanted, they show that LEAP has the potential
to lower the defibrillation energy below the pain threshold.
In the experiments we evaluated the energy gain which is possible using LEAP and found
that it is already substantial even on first tries. We also varied pacing parameters in order
to determine if LEAP efficacy can be attributed mainly to successive synchronization
of cardiac tissue or to stimulation at the “centers” of fibrillation. The answers to these
questions are given in chapter 8 and 9.
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Chapter 2
The Heart, an Excitable Medium
The heart as the most active muscle in the human body is a paradigmatic example
for a self-organized system of a special class: an excitable medium. In the healthy
heart, the initial contraction signal is given from few specialized pacemaker cells. The
excitation propagates through the heart muscle itself, reaching its farthest corners before
the heart relaxes, only to be activated again a few hundred milliseconds later. Yet many
excitable media have the ability to exhibit self-sustained spatio-temporal activity which
does not need external driving. In the heart these activities show up as several kinds of
arrhythmias, some of which can be severely life threatening.
This chapter gives an introduction to what excitable media are, some examples and
what could go wrong for otherwise comparatively reliable systems such as the heart.
2.1 Excitable Media
One of the features setting living matter apart from dead are sustained chemical reactions
which take place far away from equilibrium. This abundance of energy makes way for a
class of systems which are generally characterized as excitable media1.
An excitable medium has two specific properties: Its elements have a state with specific
properties which may change over time (governing the local dynamics) and the current
state can be communicated to the elements’ neighbors (adding one or more spatial
dimensions to the dynamics). Elements in an excitable state may, through interaction
with neighboring elements, become excited and in this state, excite their neighbors in
turn. Following this state, they drop into some refractory state before they become
excitable again. Figure 2.1 shows a schematic view of this principle.
1See for example [11] for an overview over common properties of excitable media.
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Figure 2.1: Schematic view of an excitable medium: Each element has a state and
excited elements may push their excitable neighbors into the excited state.
Of course, discrete states as in this simplified description are rare, most systems’ states
y are continuous, e.g. molecular concentrations in biological tissue. The local dynamical
behavior y(t) can then mostly be described by a set of differential equations:
∂y
∂t
= F(y, t) (2.1)
Spatial coupling in the medium is usually modeled by adding a diffusive term to the
system of local equations, resulting in the form of a so-called reaction-diffusion system:
∂yi(x)
∂t
= Fi(y(x), t) +∇Di(x)∇yi(x) (2.2)
It has been known for a long time [12] that excitable media can feature wave propagation
and even reentrant patterns such as spiral waves which survive prolonged times without
external stimulation. Figure 2.6 shows examples of such wave patterns in numerical
simulations.
2.1.1 Examples of Excitable Media
Among the best-known and oldest published reaction-diffusion systems are the Belousov-
Zhabotinski reactions (BZR) [13, 14]. In this class of inorganic cyclic chemical reactions,
malonic acid is oxidized by bromate, catalyzed by cerium or similar ions. The current
(oxidation) state of the medium can be made visible by indicators such as ferroin, chang-
ing color between blue and red. A stirred BZ medium shows cyclic changes of the color,
while in resting medium circular or spiral waves (in two dimensions) and even scroll
6
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Figure 2.2: Left and middle: Images of BZR (2D and 3D). In the leftmost image,
spontaneous circular activity and spiral waves (arrows) can be observed. The image
in the middle shows a rendering of reconstructed three-dimensional scroll waves in a
BZR medium as described in [16], with a corresponding raw image as inset. Images
courtesy of Claudia Richter, Marion Kunze, Göttingen (2D) and Patricia Dähmlow,
Magdeburg (3D) Right: Cellular automaton simulation of a plane wave traveling from
top to bottom, with a double spiral induced in the wave back. The snapshot was made
four time steps after the spiral was induced by manually setting a few pixels in the
wave back to the activated state.
waves for the three-dimensional case [15, 16] can develop (see figure 2.2, left and mid-
dle).
The simplest numerical model for excitable media are cellular automata where each cell
can switch between at least three states, as shown in figure 2.1. A set of transition rules
µ : xi(t) × Si(t) 7→ xi(t + 1) which modify the current state xi of each cell i depending
on the neighborhood Si could look like this:
xi(t) Si(t) xi(t+ 1)
excitable no excited cell excitable
excitable at least one excited cell excited
excited irrelevant refractory
refractory irrelevant excitable
This rule set was implemented using the cellular automata simulation software Golly
[17], one exemplary result can be seen in figure 2.2 (right). Cellular automata like this
have been employed for over 60 years [18, 19] as simplified representations of spreading
excitation in neuronal tissue.
One especially high-level example of excitation waves with discrete “cells” can be ob-
served in sports audiences, where human beings act as elements of the excitable medium:
Fans in a stadium may synchronize to form a so-called “Mexican Wave”, where a wave
of cheering goes through the audience and around the playing field or at least parts of
it. Farkas et al., Farkas and Vicsek [20, 21] have proposed a detailed model to describe
the dynamics of spectators reacting on the cheering of their neighbors.
Currently one of the most studied excitable media from biology are colonies of the so-
cial slime mold amoebae Dictyostelium discoideum [22]. As long as there is sufficient
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food supply, i.e. bacteria to feed on, the D. discoideum population grows by mitosis.
In contrast, under starvation the D. discoideum cells aggregate to migrate as multicel-
lular “slugs”, form a fruiting body and finally release some cells in the form of spores
which may start this cycle again. The aggregation is organized by periodic production
and emission of a messenger molecule, cyclic adenosine monophosphate (cAMP). Single
starving D. discoideum cells follow the cAMP gradient via chemotaxis, thus building the
clusters necessary for the migration and spore building part of their life cycle.
Phosphodiesterase leads to a constantly decreasing cAMP concentration through hy-
drolysis inside and outside the cells, unless more cAMP is synthesized or secreted, re-
spectively. Outside the cells, cAMP concentration also changes due to diffusion. cAMP
synthesis inside D. discoideum depends on the local cAMP concentration outside but
is limited by the current sensitivity of the cAMP sensors which become desensitized
after prolonged exposure[23]. Tyson et al. [24] were able to put this into a system of
differential equations corresponding to (2.2) which describe the evolution of the intra-
cellular and extracellular cAMP concentrations β and γ and the fraction of sensitive






β − kextγ +D∆γ (2.3)
∂β
∂t
= F (ρ, γ)− ktβ − kintβ (2.4)
∂ρ
∂t
= −f1(γ)ρ− f2(γ)(1− ρ) (2.5)
Here, kt, kext and kint describe the cAMP secretion and hydrolysis rates,D is the diffusion
coefficient and F , f1 and f2 describe the production rate and sensor (de)activation in
more detail.
With adequate parameters, this model can exhibit circular and spiral waves of changing
cAMP concentration with periods of a few minutes, just as can be found in homoge-
neously distributed D. discoideum populations.
2.1.2 Excitation and Wave Propagation in the Heart
In the heart, muscle cells (cardiomyocytes) have to fulfill a complicated task: On an ex-
ternal stimulus they must contract in a synchronized way and end this synchronization
again after some time, waiting for the next stimulus to arrive. Electrical activation and
mechanical action of the cardiomyocytes is communicated via changing ion concentra-
tions in the intra- and extracellular space.
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Figure 2.3: A selection of ion channels in the membrane of a cardiomyocyte. From
left to right: (Fast) Na+ channel, (slow) Ca2+ channel, K+ inward rectifying channel,
K+ voltage gated channel.
In the heart, there is a strong surplus of Na+ and Ca2+ ions outside and K+ ions
inside the cardiomyocytes. Ion channels allow some ions to diffuse between intra- and
extracellular space. The ion concentration gradient is kept mostly constant by selective
ion pumps in the cell membrane, which leads to an electrical potential difference across
the membrane, the membrane potential. For resting cardiomyocytes, the membrane
potential is usually between −90 and −85mV. Some of the ion channels are not static
but their conductivity is dependent on the membrane potential or specific ion or molecule
concentrations. For example the actual contraction of cardiomyocytes is induced by an
increase of the intracellular Ca2+ concentration, an effect that is amplified by calcium
sensitive calcium channels in the sarcoplasmic reticulum, an intracellular calcium storing
structure.
Once the membrane potential of a cardiomyocyte rises above a certain threshold due to
external activation, Na+ channels open and let more Na+ flow into the cell, increasing
the membrane potential even more. These fast sodium channels are only open for a
few milliseconds, but the depolarization is kept at a high level by the opening of slower
calcium channels. At the same time the constant outflux of potassium ions into the
extracellular medium is decreased and only at the end of the activation phase, 200 to
400ms after the onset, additional K+ channels open to restore the original membrane
potential; the cell membrane returns to the polarized state. The action potential, the
change of the membrane potential during activation and deactivation, is shown in fig-
ure 2.4.
While the membrane potential increases noticeably during activation of a cardiomyocyte,
it should be noted that the ion concentrations stay virtually constant since already small
9










Figure 2.4: A schematic of the human cardiac action potential. Its shape emerge
from the interaction of the cardiac ion channels. After the fast Na+ channels initiate
the upstroke, the plateau phase is maintained by slower Ca2+ channels and the blocking
of inward rectifying K+ channels. At the end of the action potential, additional K+
channels open to guarantee quick repolarization.
Figure 2.5: Gap junctions (in violet) connect neighboring cardiomyocytes and thus
allow direct communication of action potentials, mainly in fiber direction.
charges ares sufficient for significant voltage changes.
The action potential in the heart spreads to neighboring cells through the extracellular
space, but also directly from cell to cell. Cardiomyocytes are elongated cells of 50
to 70 µm length, their cytoplasm is connected directly to their neighbors through gap
junctions, mainly at the ends (figure 2.5). This anisotropy leads to significant differences
in the excitation propagation velocities along and perpendicular to the muscle fiber
orientations.
The described mechanisms, excitation amplification, depolarization and later repolar-
ization and relaying this excitation to neighbors cause the spread of excitation as waves
in cardiac tissue. In the section “Excitation Pathways in the Heart”, I will explain the
excitation of the whole heart in more detail and section “Pathological Heart Activations”
will cover pathological activation patterns.
2.2 Modeling of Excitable Media
Considering the medical importance of a functioning heart, it is understandable that ex-
tensive efforts have been made to describe the functional behavior of the cardiomyocytes
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in varying levels of detail and complexity. Mathematical models allow to understand
the mechanisms underlying cardiac behavior, in particular pathologic activation patterns
and methods to terminate them. Here I will focus on the electrical aspects, the equally
important electro-mechanical coupling is beyond the scope of this work.
2.2.1 Bidomain and Monodomain Models
In a first approximation, it makes sense to consider mainly the electric potential on
the inside and outside of cardiac muscle cells. On a macroscopic level, one can make
the assumption that both the intracellular and extracellular domain pervade the whole
geometric space, i.e. the state of each point consists of the intra- and extracellular state
at that point.
This idea can be formulated in the bidomain model of cardiac tissue:
ji and je are the current densities within the intra- and extracellular space, respec-
tively. These current densities are governed by the potentials φ. and conductivities σ.
(conductivity tensors in the case of anisotropic media):
ji = −σi∇φi (2.6)
je = −σe∇φe (2.7)
Interaction between the two domains is mediated through the transmembrane current
density jm, which scales with the surface to volume ratio χ:
∇σi∇φi = χjm = −∇σe∇φe (2.8)
If the intracellular domain does not cover the same physical space as the extracellular
domain, no-flux boundary conditions for the intracellular medium are assumed on the






The extracellular medium’s potential and current are assumed to be identical on both
sides of this boundary.
Introducing the (trans)membrane potential φm = φi−φe and the membrane capacitance
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Here the ionic membrane current jion includes the linear and nonlinear effects that make
up the cells’ behavior. In most models the overall transmembrane current is composed
of currents for different types of ion channels and pumps, many of which depend not
only resistively on the membrane voltage but also on the internal state of the cell.
Usually the previous equations are rewritten in a slightly different way which is closer










∇ (σe + σi)∇φe = −∇σi∇φm (2.12)
The equations (2.11) and (2.12) constitute the bidomain equations. The most common
way to solve such a bidomain system is for each time step to first integrate (2.11) and
then solve (2.12) for φe.
Since especially the latter step is computationally expensive for large systems, it makes
sense to consider the special case where σe and σi are not independent of each other,
but are only scaled differently as in [25]:
σi = kσe (2.13)
Putting (2.13) and φi = φm + φe into (2.8) yields:
∇σe∇φe = −k∇σe∇ (φm + φe) (2.14)
= − k








k + 1∇σe∇φm − jion(φm)
)
(2.16)
Equation (2.16), the monodomain equation, depends only on the membrane potential
φm which makes solving it numerically a lot simpler. Although the assumption (2.13)
does not hold physiologically in many cases, the monodomain representation can still
reproduce a broad range of physiological behavior qualitatively and quantitatively.
The mono- and bidomain equations are compatible with the formal requirements for a
reaction-diffusion system (equation (2.2)) with just one or two diffusive variables. Addi-
tional variables u are “hidden” in the ion current dynamics of jion = jion(φm(x),u(x))
and evolve locally according to some ∂u(x)∂t = f (φ(x),u(x)).
Together with boundary and initial conditions and a suitable f , the mono- and bido-
main equations can describe the evolution of an excitable medium which is continuously
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Figure 2.6: Numerical integration of the Barkley model on a square domain. The
color, from blue to red, indicates the value of the activation variable. Left: A plane
wave traveling in upward direction across the tissue Middle: A self-sustained spiral,
in clockwise rotation. Right: Turbulent activation in the Bär-Eiswirth model[26], a
modified Barkley model with an additional nonlinear term. The model systems were
integrated using the MediaSim software framework (main author: Philip Bittihn).
extended in space. Several methods exist to handle spatially extended systems numeri-
cally, most of them discretize space so that the system only needs to be calculated at a
finite number of sites. Typical examples of a particularly simple model (as proposed by
Barkley [9]) system are shown in figure 2.6.
2.3 Excitation Pathways in the Heart
Abnormal heart rhythms can be serious and even fatal diseases, but usually the heart
beats about 100 000 times a day without problems. Therefore it is crucial to have a
thorough understanding of how normal cardiac excitation spreads in the heart before
investigating pathological patterns.
2.3.1 Overview over Cardiac Anatomy and Mechanic Function
The heart is “optimized” to supply the body with a steady flow of oxygenated blood of
approximately 5 to 20 lmin (this and other basic physiological data are taken from [27]).
To meet this requirement, the heart is structured into four main compartments, right
and left atria and ventricles, each atrium connects to its corresponding ventricle.
During each cardiac cycle, at the beginning of the ventricular systole, the ventricles
contract, and the increasing pressure of approximately 120mmHg (in the left ventricle)
ejects about half the intraventricular blood volume into the respective arteries, which
lead into the lung (right ventricle) or via the aorta (left ventricle) into the body. Valves
prevent the blood from flowing back from the ventricles into the atria during and from the
arteries into the ventricles after the contraction. The beginning of ventricular relaxation
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marks the end of the systole and start of diastole. The aortic and pulmonary valves
close to prevent the reflow of blood into the ventricles while the comparatively elastic
pulmonary artery and especially the aorta keep up the pressure at a high level (about
80mmHg in the aorta).
The ventricular relaxation in the diastolic phase lets blood flow into the ventricles from
the atria, which shortly contract at the end of the diastole, just before the next systole
begins.
In contrast to the left ventricle (LV), the right ventricle (RV) has a systolic pressure of
only about 25mmHg.
2.3.2 Biological Pacemakers
Electrical activation in the heart is started by specialized pacemaker cells in the sinoatrial
node (SA node) in the right atrium (RA). These cells spontaneously oscillate between
polarization and depolarization and in this way initiate excitation in connected excitation
pathways. If for some reason electrical activity is not initiated in the SA node or blocked,
other cells may act as backup pacemakers, e.g. in the atrioventricular node (AV node) or
in the ventricles themselves. To prevent accidental pulse initiation in these secondary and
tertiary pacemakers, their normal oscillation rate is only about 40 and 30 beats /min,
respectively. During normal sinus rhythm, they are overdriven and reset by the standard
activation.
2.3.3 From the Sinus to the AV Node
From the SA node, the excitation spreads over the atria, whose contraction denotes the
end of the diastolic phase. The ventricles are electrically insulated from the atria so
that they cannot be directly activated. The only connection is via the AV node and
the bundle of His, the AV node is located in the RA above the interventricular septum,
the bundle of His continues from the AV node in two branches into the septum. Once
an excitation wave activates the AV node, activation does not propagate immediately
into the bundle of His, but is delayed by about 0.1 to 0.2 s. This permits the atria to
contract completely and relax again before the ventricles start contracting.
2.3.4 Bundle of His and Purkinje System
To maximize blood pumping efficiency, ventricular contraction is synchronized as much
as possible. For this purpose, the excitation signal in the ventricles is first conducted
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by the bundle of His in two branches in the interventricular septum and then further
distributed by a branched system of Purkinje fibers. In this specialized conduction
system, the propagation velocity in is increased approximately threefold compared to
the normal myocardium.
According to the endpoints of the Purkinje fiber system, normal electrical activation in
the ventricle starts approximately at the apex (the most inferior point, which is furthest
from the arterial valves) and continues to the base. Contraction continues until about
0.1 s after the whole ventricle has been activated.
2.3.5 Fiber Orientation
Cardiomyocytes are elongated cells with a width to length ratio of about 5:1. In a review
by Valderrábano [28], it is pointed out that the anisotropy of the conductivity tensor
σ is caused mainly by the particular orientation of the cardiomyocytes. The bulk of
the resistance is due to the interfaces between cells, and e.g. gap junctions are mainly
located at the ends of cardiomyocytes.
The ventricular cardiomyocytes are arranged in thin sheets of a few cells thickness which
make up the cardiac muscle structure. In each of these sheets, the single cells are typically
ordered parallel to each other with a preferred direction, winding around the heart. In
[29], Holzapfel and Ogden give further insight into this multi level structure, which
mainly serves optimal contraction of the cardiac muscle.
As a result of the hierarchical orientation structure, wave propagation in the ventricles
along the main fiber orientation is about twice as fast as in a perpendicular direction.
2.4 Pathological Heart Activations
Considering the heart’s activation and pumping mechanism is very robust, that the
majority of people live for many decades without major cardiac malfunction, but still
pathological cardiac excitation patterns may develop. The consequences can range from
being not even noticeable to potentially lethal.
2.4.1 AV Block: Time for a Backup Solution
If for reasons such as inflammation or local ischemia the AV node or bundle of His
is adversely affected, normal conduction of the activation signal from the atria to the
15
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Figure 2.7: Schematic APD restitution curve. (a) The beat-to-beat interval is iden-
tified by T , the action potential duration (for example when φ > φ0 + 0.2(φmax − φ0))
by APD and the remaining diastolic interval by DI. (b) Restitution curves are a sim-
plified way to describe the dependence of an action potential on the time since the last
action potential. Here an APD-DI restitution curve is used, if the slope is larger than
1 at APD(DI) = T −DI, there is no single stable fixed point. (c) Spatially discordant
alternans with two regions, which alternately exhibit short and long action potentials.
Figure according to [31].
ventricle may be inhibited. In these cases, as noted in 2.3.2, further pacemaker sites
take over to initiate contraction of the ventricle.
The resulting (ventricular) heart beat is significantly slower than the normal sinus
rhythm, typically less than 40 beats /min [30], because higher frequencies of the ven-
tricular pacemaker cells might interfere with the normal sinus rhythm.
2.4.2 Alternans
In some cases2, rapid heart beat from the sinoatrial node can lead to variations in
the response of the ventricular action potential. This effect, called alternans, can be
intuitively understood by considering the restitution curve which describes in the manner
of an iterated map how the action potential duration (APD) depends on the preceding
diastolic interval (DI) (figure 2.7).
If dAPDdDI > 1 at APD(DI) = T −DI, there is not a single limit cycle when the system
is being paced (from the SA node or by external pacing), but possibly alternans (a case
of period doubling) can develop. In the heart this may lead to regions of alternating
behavior (figure 2.7c). Because media in this regime is prone to more complex behavior
and patients whose ECG displays such alternans are in higher risk of potentially fatal
arrhythmias, occurrence of alternans is an important cardiological marker in clinical
practice [31].
2For example if one of the branches of the bundle of His or parts of the Purkinje fiber system is
blocked.
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2.4.3 Ventricular Tachycardia: Mostly Harmless?
If for some reason, for example due to anatomical reentry (an excitation wave reaches
medium which is excitable again through a unidirectional pathway) or from irregular de-
polarizations, excitation spreads in the ventricle before it is fully excitable, self-sustained
spiraling excitation patterns may emerge, similarly to the simulation result in the mid-
dle image of figure 2.6. Because the spiral rotation frequency is a lot faster than the
pulses entering through the AV node, the spiral is not influenced by whatever rhythm
the atrium provides.
At about 150 beats/min, this arrhythmia still makes the heart contract sufficiently to
supply the body and brain with oxygen. But although such ventricular tachycardia
(VT) is not immediately fatal, it can degenerate into ventricular fibrillation (VF) if it is
sustained and therefore constitutes a considerable threat.
2.4.4 Ventricular Fibrillation
Although the frequency of ventricular tachycardia is drastically increased as compared
to normal sinus rhythm, it is regular and synchronized across the ventricle so that the
heart can still contract. Prolonged episodes of VT however carry the risk that this
regularity is lost and that the synchronized spiral breaks up into turbulent activity. In
this state of ventricular fibrillation, different regions of the cardiac muscle are contracting
in an uncorrelated manner at different times, so that the net pumping power vanishes.
Unless treated immediately, the resulting loss of oxygen supply leads to irrecoverable
and eventually lethal brain damage within minutes.
If fibrillation occurs not in the ventricles but in the atria, the low conduction velocity
in the AV node effectively acts as a low pass filter and prevents propagation of the fast
stimuli into the ventricles.
Several mechanisms may underlie VF, the most prominent being the “mother rotor” and
wandering wavelets. In the case of a stable mother rotor spiral wave, distant regions can
not follow the spiral frequency, causing waves to break up. Alternatively, the medium’s
dynamic may allow the continuous formation and annihilation of excitation wavelets.





3.1 Termination of Arrhythmias
Cardiac arrhythmias can be terminated by shocks of high current which flow through the
myocardium. The current forces all myocytes into excitation, after the shock the tissue
is generally refractory, preventing further propagation of arrhythmic activity. After this
refractory state, the next normal sinus rhythm signal can take over again.
Clinically this shock is either applied transthoracically through a pair of electrodes at-
tached to the skin or, for patients with high risk of dangerous arrhythmias, automatically
by an implanted device. These implantable cardioverter-defibrillators (ICD) consist of a
metallic case which is usually located between the rib cage and the left pectoralis muscle
and and a catheter in the right ventricle. The catheter is fitted with a helical coil which
serves as one electrode, the ICD case is the other electrode across which defibrillatory
shocks can be delivered. See figure 3.1 for a sketch of the electric field and figure 6.6a
for a view of the catheter.
Figure 3.1: Electric field geometry between the case of an implantable cardioverter-
defibrillator and the catheter inside the right ventricle of the heart.
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3.2 External Fields and Tissue Boundaries
Obviously electric fields have effects on the dynamics of heart tissue, understanding
these effects allows to develop insights into the mechanisms of defibrillation and to
develop more efficient defibrillation methods. Sobie et al. [33] and Tung [34] showed that
both diverging electric fields and changes in the tissue conductivities can lead to local
depolarization and hyperpolarization of cardiac tissue. Fishler [35] added the relative
density of cardiomycoytes to the list of depolarization causes. The depolarization at
tissue heterogeneities can, depending on shape and size of the heterogeneity and on the
electric field strength, act as a nucleation core for new excitation waves. At minimally
effective field strengths, only the largest heterogeneities (typically the tissue boundaries)
emit waves, whereas if the electric field is at or above the defibrillation field strength
(about 6 Vcm [36]) the membrane potential of the whole tissue is elevated above the
excitation threshold.
Details about the interaction of electric fields with heterogeneities are given in more
detail in section 4.1 (Size Matters).
3.3 Pinning of Spirals
In numerical models as well as in reality, spiral excitation may move on complex paths
(see [7] for an overview), the spiral tip’s trajectory generally also depends on the structure
of the underlying tissue. Most significant in this context are heterogeneities which are
not excitable themselves, rotating spirals may attach to these obstacles and enter a
periodic steady state. Experimentally this has been observed for example at the base of
the papillary muscle [32].
3.4 Low Energy Pacing
Although defibrillation by external or internal defibrillators (ICDs) is a life-saving mea-
sure in most cases, especially ICDs are burdened by a number of drawbacks: The high
energy associated with defibrillation shocks may be detrimental to the affected tissue
[37]. Maybe more significant yet are the psychological effects. Several studies [38–40]
have found significant negative effects of delivered shocks on the quality of life of pa-
tients, this finding may well be connected to the fact that about 10% of all ICD patients
experience inappropriately delivered shocks within the first 12 months after implanta-
tion [41]. For some patients [42], the experience of ICD shocks can be traumatic enough
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to rather have the ICD explanted or deactivated than suffering another shock in spite
of the often life-saving effects.
It is important to note that modern ICDs do not deliver the full shock energy in all
cases. When the patient only suffers from monomorphic VT, it is often sufficient to
stimulate the heart locally from a small bipolar electrode at the tip of the intraventricular
catheter with a frequency higher than that of the tachycardia. Such anti-tachycardia
pacing (ATP) is commonly sufficient to drive the self-sustained spiral center into the
boundaries of the tissue (similar to an effect described in [43]). The energies involved
in ATP only need to be sufficient to excite the myocardium locally. Only if ATP fails
or is unlikely to succeed, for example in the case of VF, the full defibrillation shock is
delivered.
If it were possible to decrease the energy required to terminate even complex VF below
the perceived pain threshold, this would mean a tremendous gain in the quality of life
for ICD patients and probably also increase their physical health. Fortunately there are
physical principles by which such a reduction could be achieved.
3.4.1 Fortified Spirals
ATP is successful against freely rotating spirals because of the annihilating properties of
waves in excitable media, which allow the faster of two periodic wave sources to entrain
gradually larger regions until the whole medium is synchronized. If a spiral is pinned
to an unexcitable obstacle however, this mechanism may fail if the pacing source is
sufficiently far away from the obstacle: although the spiral tip is unpinned and driven
away, the pacing wavefront creates a new pinned free end [44].
3.4.2 Obstacles to Assets
The idea of low-energy antifibrillation pacing (LEAP) is to utilize the very tissue het-
erogeneities which inhibit ATP’s success. While unpinning and driving away of pinned
spiral is not possible when the pacing source is far away, it is feasible for pacing sources
in the vicinity (relative to the spiral wavelength) of the obstacle [45, 46]. Obviously with
a single intraventricular catheter, it is impossible to guarantee that local pacing always
occurs from very close to the relevant obstacle(s). In 1999 however, Pumir and Krinsky
[47] showed that it is possible to combine the necessity of potentially many pacing sites
with the specifically required locations: by applying an external electric field E, hetero-
geneities, including those with a pinned spiral, emit excitation waves, which can lead to
the unpinning and thereby the potential removal of formerly pinned spirals. The energy
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required for this activation of obstacles as wave emission sites should be about a factor
of 100 lower than for defibrillation.
3.4.3 Many Small LEAPs to End Fibrillation
One important restriction for LEAP success is the angle or phase of the spiral relative
to the electric field at the instant of pacing. Only if the “unpinning window” in the
phase is hit, a wave can be emitted and unpin the spiral [47, 48]. In order to increase
the chance of unpinning and thus LEAP success, a series of pulses set apart by T , T
are delivered to perform a phase scan over the spectrum of different spiral phases. With
T < T (named overdrive pacing), unpinned spirals will be driven away further from
the former pinning center.
However because even pulses which fail to unpin the spiral influence its phase, overdrive
pinning can lead to phase locking [49], so that underdrive pacing with T > T may
be more successful. These two contradicting strategies up to now remained to be tested
experimentally (some promising results could already be demonstrated in [45]).
A crucial advantage of LEAP is that it should be comparatively simple to implement
clinically without major changes currently implanted ICDs. Possibly it may even be
sufficient to just adapt the antifibrillation software to deliver a series of LEAP pulses
instead of a single high energy shock. If LEAP fails, maybe because it terminates VF
only with a finite probability, a traditional single defibrillation shock could follow.
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Chapter 4
Heterogeneities in Cardiac Tissue
As briefly explained in section 3.2 (External Fields and Tissue Boundaries), external
fields can lead to the emission of activation waves at tissue boundaries. This hetero-
geneity effect can to a certain extent also take place in structures where the medium
properties change significantly, although it is most prominent at tissue boundaries.
Both size and shape of the heterogeneities play an important role at determining the
effect an electric field has on the tissue. In this chapter I will focus on one type of
heterogeneity which is comparatively easy to quantify and nearly ubiquitous in the
myocardium, on blood vessels.
4.1 Size Matters
4.1.1 Circular Heterogeneities Modeled
To quantify the idea of boundaries as excitation sources as discussed in section 3.2,
consider a circular heterogeneity of radius R in an isotropic medium. Outside the cardiac
tissue, we assume that the extracellular properties are the same as inside (φe = φo,
σe = σo), while the missing or dead cardiomyocytes are modeled by infinite intracellular
resistance, leading to no-flux boundary conditions for the intracellular current. This,
together with charge conservation for currents across the boundary (with boundary
normal n) in the extracellular medium, can be formulated as
n · σe∇φe = n · σo∇φo (4.1)







Figure 4.1: Sketch of a circular obstacle with radius R inside an otherwise continuous
medium. The surface normal is n, the external electric field E forms an angle of θ0 to
the x axis.
where φo is the outside potential. Assuming a constant electric field E = −∇φo and the
simpler case of an isotropic medium, we can combine the two equations to:
n · ∇φm = n ·E (4.3)
For small deviations φ of the membrane potential from the resting potential, φm =
φresting + φ, the transmembrane ionic current can be linearized so that the effective
transmembrane resistance (at φm ≈ φresting) is sufficient to describe the system.
In the steady state, this means that the monodomain equation (2.16) and the boundary
condition (4.3) can be rewritten as follows:
∆φ− 1
λ2
φ = 0 (4.4)
n · (∇φ−E) = 0 (4.5)
Here λ is the electrotonic space constant governing the decay of point potential sources
over a distance, see the appendix A.1 for more details.
For the two-dimensional case of circular heterogeneities of radius R embedded into a
medium (see figure 4.1), these equations can be solved in polar coordinates (r, θ) by
modified Bessel functions of the second kind [47]:










) cos(θ − θ0) (4.6)
This solution leads to hyperpolarization at the cathodal and depolarization at the an-
odal side of the obstacle, with an effect proportional to the field strength. The exact
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Figure 4.2: The normalized maximum depolarization φ̂(R) = 1λ|E|φ(r, θ0) for given
normalized positive curvatures λR .
dependency of the depolarization on the obstacle size is plotted in figure 4.2. One eas-
ily sees that for a given electric field, there is a critical obstacle size required to reach
the threshold potential φthr which is required for activation of the cardiomyocytes. All
obstacles of this size or larger will push cardiomyocytes into the excited state and thus
serve as wave emitting heterogeneities (WEH).
Building upon these findings, Bittihn et al. [50] developed a more general theory of
the interaction of boundaries and applied electric field. It describes how the shape
and especially the curvature of the interface determines tissue depolarization. One
implication is that pieces of cardiac tissue embedded into non-cardiac surroundings also
experience activation depending on their size and that this effect can even outperform
that of non-cardiac enclosures. These results are detailed in the appendix section A.1.
4.1.2 Embedded Heterogeneities
In the heart of course, there is not just one single heterogeneity, but whole structures
which can be influenced by electric fields. For the moment we assume they can be
modeled as spatially discrete obstacles oi with sizes much smaller than the distances
between neighboring obstacles. Then for an applied electric field of a given strength,
some of these obstacles emit spherical (or, in the case of a homogeneously anisotropic
medium, elliptical) excitation waves which spread until the whole medium has been
activated.
These heterogeneities which are embedded into the excitable medium are expected to
play a crucial role both in the genesis and the sustainment of turbulent spatio-temporal
activation patterns and in the termination thereof:
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• The presence of heterogeneities in an otherwise homogeneous medium can lead to
wave breakup and therefore turbulent behavior [51–53].
• Spiral or scroll waves (in two or three dimensions, respectively) tend to pin to
heterogeneities in the medium, which may also stabilize the turbulent state against
plane waves trying to synchronize the medium [44, 54, 55].
• In contrast to the previous two points, heterogeneities may also serve as wave
emitting sites and thereby help to terminate fibrillation-like turbulent states [45,
47].
4.2 Heterogeneities in the Heart
In cardiac tissue, heterogeneities of many types and geometries exist. Some are bound-
aries where the myocardium and fluids or other tissue types meet, while others are
formed by more or less subtle changes of physiological properties.
Among the first kind are:
• The epicardial (outside of the heart) boundary of the heart: The heart is embedded
into a flui filled sac, the pericardium [56], which protects the heart and eases its
movements by providing lubrication. The epicardium as a heterogeneity has a
negative boundary curvature as described in section A.1 in the appendix.
• The endocardial (inside of the heart) side of the heart: While the epicardium
is comparatively smooth, this is not the case for the endocardium. To support
the heart’s blood pumping, it is structured in a complicated way, with different
characteristics in the atria and the ventricles. Some of the endocardial atrial
walls have muscular links, the pectinate muscles. Similarly, the ventricles are
strengthened on their interior by columnar muscles, the trabecular muscles which
run along the ventricular walls. Additionally the ventricles have papillary muscles,
column-like muscles which are attached to the inferior ventricle walls at one end
and prevent the atrial valves (connected by the chordae tendineae, fibrous strings)
from opening into the atria during the systolic phase. Figure 4.3 illustrates the
anatomical features of the ventricular and atrial endocardium.
While the overall curvature of the interior cavities of the heart (atria and ventri-
cles) is of course positive, the complicated structure at smaller scales prevents the
assignment of a single typical size which would describe the behavior completely.
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Figure 4.3: The structure of the endocardial walls as seen in the left ventricle and
the atrium. Note the papillary muscle and trabeculae (white arrows) in the ventricle
and the pectinate muscles in the atrium (black arrow).
• Coronary vasculature: Being permanently active, the heart needs a reliable and
powerful supply of oxygen and nutrients. Only in small animals where the heart
walls are smaller than on the order of 1mm, direct diffusion from the atria and ven-
tricles into the myocardium is sufficient to play a significant role for the muscular
oxygenation.
In larger hearts however, oxygen and nutrient are provided by a system of blood
vessels, the coronary vasculature, which branches directly from the aorta. This
vascular system is omnipresent in the myocardium, and traverses it whenever nec-
essary, although the larger vessels run mainly on the myocardium or very close to
the surface [57]. In two-dimensional cross-sections, the blood vessels can be seen
as circular obstacles where the response to external electric fields follows equation
(4.6).
For further references on cardiac anatomy, see e.g. [56].
In the second type of heterogeneities the myocardium does not abruptly cease to exist.
This type contains modifications of cardiac tissue, by natural causes such as fat deposits,
but also scarred tissue after surgeries or fibrotic tissue after myocardial infarctions.
These heterogeneities may be locally confined or nearly everywhere in the heart and
they may show different degrees of severeness. While it may be impossible to give
analytical results of how they react to external fields, they certainly can serve as WEHs,
as long as they change the relation between intra- and extracellular space enough to
induce current flows across the cell membrane.
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Heterogeneities in the sense of this type do not need to be of different tissue types. Also
local changes of the fiber orientation as described in section 2.3.5 can effectively result
in conductance changes and thereby lead to wave emissions.
Of all the different kinds of heterogeneities, there is one with distinct properties, it is
ubiquitous in the myocardium, there is absolutely no wave propagation inside and its
behavior can be described exactly: The coronary blood vessels. For these reasons I will
concentrate in this chapter on the interaction of vasculature with electric fields and how
it may be used to influence arrhythmias like fibrillation.
4.2.1 Cardiac Vasculature
Since blood vessels are one of the main candidates for wave emissions in the bulk tissue,
the geometric structure of the coronary vascular tree is of primary interest. Additionally
to theoretical considerations, luckily some of its properties like size and connectivity are
relatively simple to measure and quantify in animal models.
It has long been known that hierarchical biological systems tend to to follow power law
scaling in their sizes due to metabolic optimization [58–62]
In 1926, Murray showed in [58] that basic laws for vascular structures can be derived
from the assumption that the metabolic work to keep up the blood flow is minimal.
Specifically, the volumetric flow rate q is proportional to the cubic blood vessel diameter,




r3i for child branches i. (4.7)
70 years later, Zhou et al. were able to show that the total lengths and volumes of arterial
networks, the diameter of common parental artery segments and the flow should follow
power laws in order to minimize the metabolic cost for the organism. Similar relations
had been found earlier for the pulmonary [63] and renal system [64].
Consider the radius r of a vascular tree stem (see figure 4.4 for the stem/crown nomen-
clature as used in [62]) and the flow q through this tree. By denoting the total volume of
the tree by V and the total length of all vessels by L, the following power law relations
and relations between the exponents hold:
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Figure 4.4: Structure of a vascular subtree split into a crown and a stem, as used by
[62]. Each subtree i starts with a stem stemi which continues until the first branching,
all following vessels are summed up into the crown crowni. This nomenclature is valid
recursively for all levels.
V ∝ LξV L (4.8)
r ∝ LξrL (4.9)
q ∝ rξqr (4.10)
with
ξV L + 4ξrL = 3 (4.11)
ξrL · ξqr = 1 (4.12)
With this knowledge it makes sense to expect a power law for the blood vessel size
distribution as well. We will define such a distribution in the following way: Consider
the vascular tree as a set of segments of length li (with L =
∑
i li). The question we now
ask is th following: what is the probability Pr(r) to measure the radius r if you randomly
pick one point along the whole tree and does the probability scale as Pr(r) ∝ rα? And
if it does, does α depend on the species or other factors?
4.2.2 Other Vascular Scaling Laws
The scaling exponents between e.g. volume and length of vascular trees or flow and
vascular size were found to be mostly comparable for pigs, rats, cats, humans and
hamsters and for different vascular branches [62]. Figure 4.5 shows the distribution of
values for the exponents ε′ and β from table 2 of Kassab [62] (which can be identified
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Figure 4.5: Exponents ε′ and β as given in [62]. Each symbol stands for one exami-
nation of a vascular branch in several subjects of one species (4 ≤ N ≤ 17), diamonds
(_) denote measured ε′ and circles () stand for β, the error bars show the exponents’
standard deviation.
with 5ξV L − 1 and ξV L, respectively, from the equations above). Although there are clear
differences between some data samples, the exponents are mostly consistent between
different species.
4.2.3 Size Distributions in the Literature
Although several morphometric relationships as the above-mentioned have been re-
searched before, there are no reports about the overall scaling of cardiac vasculature
diameters. Fortunately however, I could use some of the data produced in these previ-
ous studies to obtain approximations for the investigated size distribution scaling.
In [65], Kassab et al. examined the diameters and length ratios of arteries before and after
branching as a function of the vessel segments order. In their nomenclature, capillaries
and arterioles have orders 0 and 1, respectively. Parent segments are of order n + 1 if
their children are of order n and smaller by a specified amount, else they are of order n
(the order of their largest child) as well. Kassab et al. measured the smaller vessels (up
to order 5–6) in a few samples of histological slices and the larger ones in macroscopic
polymer corrosion casts.
For several cardiac tissue types, this article lists, for each vessel segment order n, how
many segments (Nn) of the respective order were found, their mean diameter Dn and
mean length Ln. Under the assumption that the length L and diameter D of a segment
are not correlated except by its order n, this data leads to a size distribution Pr(r) for
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(a) Ultrasound (b) Microscopic (c) µCT
Figure 4.6: Examples of several cardiovascular blood vessel imaging methods. (a) Ul-
trasound cross section through a rabbit ventricle with two large blood vessels (arrows).
Image courtesy of Jan Christoph, Göttingen (b) Laser scanning microscope fluorescence
image (microtomic section) of a coronary artery (red: Alpha-actinin, binds to cardiomy-
ocytes, green: Lectin, binds to endothelial cells). (c) µCT cross section through pig left
and right ventricle (gray). Blood vessels are visible throughout the tissue, filled with
contrast agent (white in this representation).
the given data set at rn = Dn/2:
Pr(rn) ∝ Nn Ln (4.13)
4.3 Blood Vessel Measuring
There are several methods to experimentally measure the sizes of coronary blood vessels
ex vivo, some of which are also, to a certain extent, applicable in vivo.
4.3.1 Measurement methods
For sufficiently large vessels or vessels that are close enough to the surface, the size
can be measured with ultrasound imaging. This method is comparably fast and works
non-destructively, thus it may be applied during the course of experiments. Figure 4.6
shows examples of ultrasound vascular images and of other methods.
Thie highest spatial resolutions can be achieved with microtomic sections imaged by
microscopes, this allows the measurement of blood vessels down to the capillary level.
This method comes with several downsides however: Full microtomic imaging of large
organs such as the heart requires a lot of manual work since thousands of slices (with
a thickness on the order of a few micrometers) need to be cut, scanned and aligned to
a three-dimensional image stack. Additionally the process of embedding the tissue into
a medium, slicing and staining is prone to distort the organic tissue which makes the
subsequent aligning difficult and introduces artifacts in the resulting volume data.
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Figure 4.7: In a CT scan, a series of two-dimensional X-ray images is taken of a
sample. From this image series the original attenuation volume information can be
reconstructed approximatively.
In recent years, other methods have gained increasing popularity: MRI (magnetic res-
onance imaging) and CT (computed tomography) are not only invaluable for clinical
diagnostics but may also be used for research purposes. These imaging techniques pro-
duce volume data organized in voxels (volume elements), which can then be analyzed
further.
In this work, I will concentrate on CT, which has a generally higher spatial resolution
and lower costs. For application in living humans, MRI may be favorable, since it
does not have the high X-ray exposure associated with CT scans. For ex vivo imaging,
radiation safety is of no immediate concern, since the samples can usually be scanned
in fully enclosed scanners which keep radiation at a safe level on the outside.
4.3.2 µCT scans
Computed tomography produces volume information of an object by taking a series of
two-dimensional X-ray images at different angles (see figure 4.7). In these images the
intensity I of each point reflects the attenuation of the X-ray beam through the observed
sample according to the Beer-Lambert law








Here µ(x) is the attenuation coefficient for a specific volume element of the sample,
and the integral runs along the beam from the X-ray source to the point (u, v) on the
detector screen.
From the acquired series of two-dimensional images it is possible to calculate the orig-
inal values of µ(x) in the sample, by combining filters with a back projection of the
attenuation values into the original space.
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soft tissue 1.693× 10−1







Table 4.1: X-ray mass attenuation coefficients for several media at 100 keV photon
energies. Note that these are mass coefficients and thus need to be scaled with the
medium density to get the volume attenuation µ as used in (4.14). Values are cited
from [66–68]
With specialized devices, computed tomography allows spatial resolutions to below 1 µm,
which is three orders of magnitude smaller than in clinical application. Usually the high
resolution computed tomography is called “micro-CT” or just “µCT”.
Since the information returned by µCT is the local attenuation coefficient, measuring
blood vessel geometries requires that the blood vessel be linked to X-ray attenuation.
Unfortunately, the intensity of water or blood on CT images is practically indistinguish-
able from the intensity of soft tissue or muscle, as can be seen in table 4.1. The preferred
method to make the vasculature visible is the injection of high-attenuation media. (It
is also possible to create contrast through replacing fluids by air, for example in the
digestive tract. For vasculature this method is not applicable due to the small sizes of
the blood vessels.) Elements with high atomic numbers are best suited for this task, but
of course also biocompatibility plays a role.
When complete solubility of the applied contrast agent is not required, an aqueous
suspension of barium sulfate, BaSO4, can be used. Generally a toxic element, barium
can be applied in this form because BaSO4 it is virtually insoluble in water and alcohol1.
The high attenuation coefficients of barium and sulfur, combined with the increased
density of the suspension results in very high attenuation. In this case the attenuation
can reach levels where the Beer-Lambert law (4.14) in the presented simple form is
not sufficient anymore: because µ is not independent of the wavelength, typically low
energy photons are absorbed more than those with higher energies. This “chromatic”
effect know as beam hardening can then lead to artifacts around high contrast areas in
the reconstructed image (see figure 4.8 for an example). Another problem connected
with the use of BaSO4 as a contrast agent is the sedimentation un undissolved BaSO4
1approximately 0.0003 g/100g H2O at 100 ◦C [69]
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Figure 4.8: Beam hardening in a CT scan: note the dark and bright streaks around
the bright spot (vessel filled with contrast agent). The contrast agent attenuates X rays
of some wavelengths more than others, this non-linear behavior can not be compensated
by the reconstruction algorithm.
particles which takes place within a few hours, this time span becomes relevant when
scanning for an extended amount of time.
Another common contrast agent, attractive because of its high atomic number 53 and
because it is relatively harmless to higher organisms, is iodine. In the simplest case, an
aqueous solution of I2 and KI under the name Lugol’s solution is used. The disadvantage
of this contrast agent for measuring the vasculature is that the dissolved iodine ions
are small enough to diffuse easily into the surrounding tissue and increase the X-ray
attenuation there as well. This issue can be circumvented by embedding the iodine into
larger molecules which diffuse much slower. Iodized alkanes for example are readily
available from commercial chemical suppliers.
To minimize artifacts from morphological changes of the surrounding tissue due to drying
up or uptake of fluids and to increase the available contrast, it is also possible to fill the
vasculature with hardening polymer. Then after the polymer is cured, the surrounding
tissue can be corroded away so that only the polymer structure inside the blood vessels
remains. This corrosion cast method has been extensively described in the literature,
for example in [70] and [71]. After creating the corrosion cast, the resulting structure
can be measured either manually or with tomographic methods as described above. The
many steps involved make the corrosion cast method is comparatively work intensive,
though.
4.3.3 Preparation and Scanning of Cardiac Tissue
In the scans in this work, quantitative analysis was done with leaded polymers and
1-iodooctane as contrast agents, some images shown used barium sulfate.
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Figure 4.9: Results of µCT scans. The first image shows an unmodified two-
dimensional view of a pig heart with contrast agent injected into its coronary vascular
system (dark tree-like structures). In the second image, three-dimensional volume in-
formation was reconstructed from the same specimen. The image shows a maximum
intensity projection (MIP), i.e. the intensity of each pixel corresponds to the maximum
intensity along its line of sight. The image to the right shows a cross section through
the reconstructed volume at the level marked by a white line on the left and middle
image. One can easily distinguish air (black, on the outside), tissue (gray) and contrast
agent filled vessels (white).
The hearts used in this work originate from animals used in other research experiments.
The handling of the animals and the experimental procedure were performed in accor-
dance with the respective national legal requirements. After the end of the experiments,
the animals were administered heparin (approximately 400 IU/kg) to prevent blood co-
agulation inside the vascular system after the animal’s death.
The heart was retrogradely perfused with the contrast agent at a pressure that was
sufficient for a constant flow of medium into the heart. For the dog hearts this was done
shortly after the finished experiment while the pig hearts were preserved for a prolonged
time in 4% formalin solution2 before administration of the contrast agent.
To achieve the necessary high resolutions, long exposure times (up to several seconds per
single image, several images were averaged for noise reduction) and many images (the
number of necessary images increases linearly with the resolution, it should be greater
than the number of sensor pixels orthogonal to the rotational axis) are necessary. The
resolution requirement therefore lead to overall scan times of several hours.
Figure 4.9 shows a µCT scan example, at 60 µm resolution. The scan took 4 hours, the
resulting volume measures 1400 voxels× 1440 voxels× 1377 voxels, which corresponds to
84mm3 × 86mm3 × 83mm3. Cardiomyocytes, for comparison, measure about 50 µm in
length with an approximate 5 : 1 ratio of length vs. diameter.
2Roti-Histofix, Carl Roth GmbH, Karlsruhe, Germany
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4.4 Automatic Size Reconstruction
To obtain the size distributions of the coronary vasculature of hearts, scanning and
reconstructing the volume information must be followed by size measurements. While
the actual measurement of vessel sizes could be done by hand, the time needed for this
procedure would render the manual measurement of large numbers of size distributions
infeasible.
The problem of obtaining vessel size statistics from a set of voxel data can be split into
two separate tasks: First finding where the blood vessels are located and second what
their sizes are.
4.4.1 Locating the Vascular Tree
The coronary arterial vasculature can be thought of as a forest of disjoint trees of blood
vessels in which each tree starts at the aorta. Immediately after the aortic valve, two
arteries branch from the aorta to supply the heart muscle itself with oxygen and nutrients
[57]: The right coronary artery feeds most parts of the right ventricle and the atria,
especially the SA node. The left coronary artery branches into two nearly equally sized
arteries very shortly after the aorta. Its descendants are the left anterior descending
artery, which goes straight down until the apex, and the left circumflex artery, which
runs along the heart’s base and supplies the left atrium and the remaining parts of the
left ventricle.
There exist several methods in the literature to semi-automatically track blood vessels
on images based on user assistance [72]. In those cases the user has to manually specify
e.g. endpoints of blood vessels and an algorithm finds an optimum way along the blood
vessels to connect the given points (figure 4.10). The “optimum way” in this context is
usually defined by traversing as few voxels of as much intensity as possible. Although
this is already much more efficient than fully manual segmentation, it does not yet make
identification of the full vascular tree possible.
Automatic methods to locate all coronary vascular vessel may require the user to enter
some initial information such as expected intensity ranges or starting points of the main
coronary branches. After obtaining this data however, an automatic algorithm must be
able to continue without further user interaction until all blood vessels have been found.
The algorithm I developed in the course of this thesis [73] to find all vessels is based
on thresholding and subsequent thinning of the obtained structure, followed by criteria
to remove structures caused by scanning artifacts. The algorithm was implemented in
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Figure 4.10: In the semi-automated vessel segmentation proposed in [72], the user
has to manually identify a number of characteristic points of the arterial vasculature
on images of the patient. The algorithm then connects these points using the contrast
agent as an indicator of the optimum path.
Raw image data Thresholding Skeletonization
Size statistic
2r
Slice orientation and fit Skeleton cleaning
Figure 4.11:
Overview over the general structure of the size measurement algorithm:
• Thresholding
• Skeletonization
• Skeleton analyzation & removal of surfaces, exceedingly large vessels and small
trees
• Orientation and size for each center line voxel
This algorithm creates a list of vessel elements with position and radius from a
volume image, the result is plotted graphically as a three-dimensional rendering where
each calculated size corresponds to the color at its respective coordinates.
Java as a plugin to the image analysis platform Fiji [74], a distribution of the widely
used ImageJ [75] program. In the plugin I made use of numerical libraries provided by
the Apache Commons project [76]. An overview over how the program works is shown
in figure 4.11.
In the first step, the volume image is segmented into high and low intensity voxels
according to user input, high intensities correspond to high X-ray attenuation and thus
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Figure 4.12: Visualization of the skeletonization process. Voronoi cell artifacts can
be caused by stray black voxels and vessel protrusions may lead to unintended skeleton
branches. Note that these sketches are two-dimensional, but the underlying effects
occur analogously in three dimensions as well. (First published in [73].)
probably to contrast agent, in the vessels and elsewhere. Thus it is reasonable to assume
that the blood vessels’ center lines are completely within the set of high-intensity voxels
— except those places the contrast agent failed to reach and very small vessels, for
which the scanner resolution was not sufficient. To extract a center line of exactly
one voxel thickness, the resulting thresholded image was successively thinned using a
skeletonization algorithm described by [77]. This algorithm results in a set S of skeleton
voxels ~x which contain information about their distance d to the next low intensity voxel:
S = {(~xi, di)}
The size measurement plugin for this work uses an implementation of the thinning
algorithm that existed already as a skeletonization plugin to ImageJ [78, 79].
Without noise and artifacts of preparation and scan in the volume data, this procedure
would result in skeleton trees3 of voxels that lie in the center line of the coronary vascular
system. Unfortunately thinning algorithms like the aforementioned one are sensitive to
small voxel classification errors, e.g. due to noise or reconstruction artifacts:
Noise The thinning process is sensitive to single voxels that are wrongly marked as
black instead of white, as can be seen in figure 4.12. Low intensity (“black”)
regions inside volumes classified as high intensity will expand during the thinning
process, leaving a thin wall around them (right hand side image in figure 4.12)
instead of the expected one-dimensional filament. For several single black voxels,
the resulting wall represent the boundaries of the Voronoi cells corresponding to
the defects.
Conversely, single white voxels would not be changed and become their own 1 voxel
tree. Erroneously marked black or white voxels may arise from noise in the original
X-ray images, which can be countered to a certain degree by averaging over many
images. This further increases the scan time, of course.
3Here trees are understood in the sense of graph theory: A tree is a connected graph where the edges
do not form loops.
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Skeletonization ambiguities Another problem may arise when the vessel shows pro-
trusions which can lead to spurious branches of the skeletal tree (left image in
figure 4.12). These unphysiological branches need to be removed in later stages.
Spilled contrast agent While filling the coronary vascular system with contrast agent,
sometimes spilling of contrast agent on the outside of the sample cannot be avoided
completely. This leads to additional high intensity regions in the resulting volume
data which produce yet more artificial skeleton trees.
Contrast agent in the ventricles and atria Perfusion of whole hearts with contrast
agents is usually done retrogradely through the aorta. At a sufficiently high pres-
sure, the contrast agent will flow into the coronary arteries which start shortly
after the aortic valve. Some contrast agent however inevitably also passes through
the aortic valve into the left ventricle and possibly also into the left atrium. Con-
trast agent returning through the venous system may also end up inside the right
atrium.
In the reconstructed CT image, the ventricle and/or atrium can then be clearly
distinguished from the surrounding tissue. Depending on the miscibility of the
contrast agent with the previous filling fluid and on the relative density, there will
be one or more relatively large connected regions of high intensity, at the bottom
or top of the left chambers and in the aortic trunk which are also reduced to some
kind of skeletal structure in the skeletonization process.
To yield a skeleton of one single voxel thickness as a faithful representation of the vascular
structure, the above mentioned artifacts are removed in a number of additional steps:
• Remove voxels whose distance di is larger than a predefined threshold dmax. This
threshold is usually chosen to be slightly larger than the diameter of the largest
coronary artery where it joins the aorta. After this step, the skeleton is reduced
to S = {(~xi, di) | di ≤ dmax∀i}.
This pruning removes unwanted contributions from the aorta or even contrast
agent filled ventricles or atria.
• Additionally all skeleton points with 6 neighbors (out of the possible 26 neighboring
lattice positions) or more are removed. This procedure cleans the skeleton from
surfaces which stem from dark voxels included within white areas.
• In a next step, the remaining skeleton is segmented into a number of disjoint trees
using the AnalyzeSkeleton [79] Fiji plugin. If there are loops within the skeleton
graph, the edge with the smallest size d is removed. There are two criteria in place
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which need to be fulfilled by skeleton trees and the branches of each tree, otherwise
they are removed:
1. For each tree i, count the number of voxels ni in this component i. Remove
the tree if ni < c
∑
i ni with c being a fixed fraction parameter, typically
0.05. This is an effective measure to remove artifacts from small spots of
contrast agent in other places than the blood vessel system, e.g. on the atrial
or ventricular endocardium.
2. For each leaf branch j (that has only one voxel with more than two neighbors)
get the length lj and distance to black dj at the connection to the main tree.
Remove this leaf branch if lj < di. This removes spurious branches as in
figure 4.12, image on the left.
From the thus reconstructed vasculature skeleton, it is possible to accurately measure
the blood vessel sizes.
4.4.2 Accurate Size Measurements on the Vascular Tree
The size of a vessel is measured in the two-dimensional plane perpendicular to the vessel
direction. In the case of contrast agent filled vessels, this problem reduces to finding the
size of a shape which best describes the intensity distribution as shown in the examples
of figure 4.13.
To derive the cross section for each point i on the skeleton structure, the reconstruction
program estimates the local direction ti from the positions of the neighboring skeleton
voxels. Up to 4 · di neighboring voxels are considered for this direction approximation,
where di is the same distance as used for the branch pruning above.
There exist a number of algorithms (see the info box on the facing page) to measure
the size of a roughly circular shape in 2D. However, most of these algorithms are com-
putationally expensive because they operate on the full two-dimensional plane. This
means that the runtime cost T (ri) to measure the radius ri, including actually acquir-
ing the plane data from the raw volume, grows at least quadratically with the radius:
T (ri) ∈ Ω(r2i ). One additional problem is that the user (or program) usually needs to
provide at least the approximate expected size in advance in order to deliver a fitting
cross-sectional plane.
In contrast to this, the algorithm used in this work does not take into account the whole
plane, but only samples the volume along a number of directions, which enables us to
bound the computational complexity linearly from above: T (ri) ∈ O(ri).
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(a) (b)
Figure 4.13: Vascular sizes are measured from cross sections through the CT image.
(a) Schematic cross sections of a blood vessel along its center line. (b) Typical blood
vessel cross sections, the diameter may span the whole range from several millimeters
down to the resolution of the acquired image, 60 µm in this case. Brighter pixels
correspond to higher X-ray attenuations. Figure first published in [45].
Detection and measurement of circular objects
Detecting circles and ellipses is a common problem in digital image analysis, with many
possible solutions:
Area detection Once the included area A has been calculated, e.g. with a threshold
operation, calculate the center as the center of mass and the radius as r =
√
A/π.
Hough transform Requires an edge detection of the image first. All pixels on the
boundary of the circle add weight to all points in the parameter space 〈x, y, r〉
which are compatible [80]. The maximum in this parameter space then constitutes
the measurement. The parameter space grows to 5 dimensions for general ellipses.
Boundary fit The boundary, once detected, is fit to a parametric curve describing the
circle or ellipse.
All these methods share the limitation that they need to process O(r2) pixels.
Specifically, the size estimation program repeats the following procedure for each skeleton
voxel i until convergence is reached or a maximum number of iterations nmax has passed:
• Sample intensity data along 4 lines through the estimated vessel center, perpen-
dicularly to the vessel direction, angled at 45° to each other. The length of these
lines is chosen to be three times larger than the previously estimated diameter
2rn−1i . During the first run (n = 0), use the skeleton coordinates as the center and
the distance to the background di = 2r0i as initial guess for the diameter.
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The Gaussian step function
In the “Gaussian step function” (4.15) the parameter σ denotes the width of the fall-off
region, a measure for the resolution of the tomography data. For σ = 0, it becomes the
ideal step function, while for r̂ = 0 we get the well-known Gaussian function I(x) =
b+ a · e−
x2
2σ2
For a typical curve of the Gaussian step function, see the schematic below or figure 4.13b.






• Fit the following function describing a double step function with a Gaussian fall-off
to the intensity values I(x) along each line:
I(x) = I(x)a,b,r̂,σ,x0 =
 b+ a if |x| < r̂b+ a · exp (− (r̂−(x−x0))22σ2 ) if |x| >= r̂ (4.15)
Here b is the base intensity of the background and b+ a the intensity of the blood
vessel. The true radius of the blood vessel can now be estimated by rni = r̂ + σ,
x0 gives the center of the vessel.
• In order to accept these values, 2rni must be between 40% and 70% the length of
the sampling line.
Otherwise, the procedure is repeated using larger or smaller values, respectively, for
the size of the blood vessel, with the vessel center taken from the latest estimates.
This algorithm finally yields a vessel size for every point along the skeleton, along with
a more accurate spatial location for each point. Figure 4.14 shows a graphical represen-
tation of such a reconstruction, the vascular sizes are color-coded and overlayed over a
maximum intensity projection of the original CT scan.
4.4.3 Accuracy tests
To evaluate the accuracy of the presented method and the effective resolution of the
µCT scanner, I tested the procedure for cylindrical objects of known sizes.
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Figure 4.14: Graphical result of a vascular size reconstruction. In this maximum
intensity projection, the color-coded radii are overlaid over the original image.
I used glass fibers of known diameters for this purpose, glued together in a tree-like
structure. I scanned this phantom with the µCT scanner which was also used for the
size analysis of the porcine hearts.
The resulting detected radii are shown in figure 4.15, they agree with the glass fibers’
nominal sizes with an error of less than 1 voxel length.
4.5 Measuring the Size Distributions
To measure the size distribution in the cardiac coronary vasculature, we acquired µCT
data from the atria and ventricles of adult beagle dogs, which were used in in vivo and
ex vivo LEAP experiments previously (for more details on these experiments and the
µCT reconstruction, see [45]). This also gave us the opportunity to retrospectively relate
potential peculiarities in the dynamical behavior during the experiment to the structure
of the heart.
4.5.1 Data Acquisition of Dog Heart Vessel Sizes
Five atrial and three ventricular dog heart wedges were scanned [45] in a µCT scanner4 at
25 µm voxel resolution in all directions, after injection of 1–2mL of Microfil5 immediately
4GE CT120, GE Healthcare, Little Chalfont, UK
5Flow Tech Inc., Carver, MA
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Figure 4.15: The detected “blood vessel” sizes for a phantom made of glass fibers.
The voxel resolution was 60 µm, the glass fibers had nominal radii of 0.25mm and
0.50mm.
following the ex vivo experiments, via the same catheter that was used for the perfusion
during these experiments. This contrast agent’s radiopacity is based on its lead content;
it is fluid initially, but polymerizes in the hours following administration.
The scanner’s X-ray source was set to 80 kV at 32 µA. From 1200 equally spaced pro-
jections over 360° we obtained reconstructed images of 25 and 50 µm voxel resolution.
The volume images were cropped and preprocessed in order to lessen the influence of the
catheter which was clearly visible and to reduce the memory requirements. To decrease
the random noise of the data, a spatial median filter (over a 3× 3× 3 voxels cube) was
applied as necessary.
I applied the size reconstruction algorithm described in 4.4 to these data sets on high
performance computers available at the Max Planck Institute for Dynamics and Self-
Organization (16 CPU cores, Intel Xeon E7340 at 2.4MHz with 4Mi B cache, 64Gi B
RAM, Linux 2.6.32). The reconstruction procedure took between one and two hours for
each data set on these computers.
4.5.2 Porcine Blood Vessel Sizes
To compare the blood vessel size distribution to that in hearts of another species, I
adapted the procedure that was used previously in dog hearts and performed supple-
mentary size statistic measurements in pig hearts.
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I prepared N = 7 pig hearts for µCT vasculature scans after they were used in the LEAP
experiments described in more detail in the following chapters 6 and 7.
After the end of the experiment, the hearts were first perfused with a hyperkalemic
solution to assure a diastolic state and then flushed and covered with 4% formaldehyde
(Roti-Histofix 4%6) in order to preserve the heart until the scan.
As contrast agent I chose a mixture of 10% iodo-octane (C8IH177) and 90% dodecane
(C12H267). The iodine content gives enough X-ray contrast to show even small vessels,
combined with several advantages over the previously used BaSO4. Since it is a fluid, it
will not block the capillaries and there is no risk of sedimentation as could be observed
with BaSO4 suspensions during prolonged scans. Additionally we observed several cases
of BaSO4 diffusion into the tissue (possibly at fissions of the aortic walls), an effect that
should be much less pronounced due to the higher molecular weight of iodo-octane. It
shares these properties with the, commercially not available, oil-based contrast agent
Angiofil [81].
At least one hour before the µCT scan, the heart was removed from the formaldehyde
solution and the formaldehyde in the heart chambers and on the surface was removed.
The coronary vasculature was then manually filled with the contrast agent via catheters
leading directly into the left and right coronary arterial branch, respectively. We found
that staining the contrast agent with red Sudan III8 helped to apply the correct volume
and pressure while filling the vascular system.
The pig hearts were placed in a custom-made acrylic glass container onto low-density
foam plastic which was of significantly lower intensity than the water-based heart tissue.
The acrylic glass container also doubled as a “water” phantom of 0HU9 intensity. In
this container, the pig hearts were scanned in a Phoenix Nanotom µCT scanner (GE), at
100 kV and approximately 90 µA with 2600 angular steps. Scanning of one sample took
approximately nine hours. The scanner images were automatically corrected pixel-wise
by their respective dark-image and response to increasing X-ray intensity.
After the scan, the images were corrected for potential movement artifacts during the
scan and the volume image was reconstructed at a spatial resolution of around 60 µm.
The contrast agent in the blood vessels had an intensity of up to approximately 1500HU
(see also figure 4.16 for a visualization of the intensity values and figure 4.17 for a three-
dimensional rendering).
6Carl Roth, Karlsruhe, Germany
7Sigma-Aldrich, Seelze, Germany
8Sigma-Aldrich, Seelze, Germany
9Hounsfield Units (HU) denote the relative X-ray attenuation of a medium. The Hounsfield scale is
normalized so that vacuum has −1000HU and water has 0HU.
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Figure 4.16: Cross section through the reconstructed µCT volume of a pig heart.
The intensity of muscle tissue is at around 0HU, fatty tissue is slightly below. Blood
vessels that are filled with contrast agent are at about 1000HU and above, a value that
is comparable to bones. The left ventricle (LV) is at the bottom, the RV at the top,
also visible are parts of the atrioventricular valves and of the atria (in the right image
half). The intensity values along the white line in the lower right are shown in the plot
on the right hand side.
Figure 4.17: The reconstructed view of a pig heart. Tissue is shown as semi-
transparent, the contrast agent is red. The LV is at the right, the RV at the left
and the apex at the bottom of the figure. The spatial resolution for the rendered image
is 150 µm, the heart is 83mm wide.
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After preprocessing as described for the dog hearts (mostly cutting away unnecessary
parts of the volume), the volumes of approximately 15003 voxels were subjected to the
same size analysis programs on the Max Planck Institute’s computing cluster. This
computation took approximately 9 hours for each data set.
4.6 Electrical Tissue Activation
As stated before, heterogeneities may serve as excitation wave sources (wave emitting
heterogeneities, WEH ) under externally applied electric fields. In quiescent tissue, these
waves will eventually excite the whole tissue, this process can be described by the acti-
vated area A(t), the part of the tissue which has been activated already. Observing A(t)
under controlled conditions allows to draw conclusions about the underlying structure of
the tissue and its interaction with electric fields. The methods described in this section
have been published in [45] and more details are given in [82].
A(t) will grow as the cumulative volume of the emitted waves, initially proportionally
to tD for D dimensions. The time τ required to activate all of the tissue can also be
quantified, at least if the N WEHs are distributed homogeneously in the medium of
volume V . In this case, the distance d between two neighboring WEHs and the wave











Since the minimum size for obstacles to turn into WEHs decreases monotonically with
growing E, more and more obstacles are recruited at higher field strengths, leading to
shorter activation times. The minimum size Rmin of an obstacle to achieve a sufficient
depolarization φ0 for a given electric field strength E is plotted in figure 4.18. For
sufficiently small obstacle sizes, Rmin decays like 1E .
4.6.1 Activation Time Measurement
Several methods exist to measure the tissue activation: Electrodes sampling the mem-
brane potential at different locations [83], mapping of mechanical contraction via ultra-
sound [84] and the use of voltage or ion concentration sensitive dyes all allow to obtain
data on how excitation fronts propagate and which effects heterogeneities have on the
tissue. Because it provides the best spatial resolution and is less invasive than the other
methods, we focused on the latter option to measure the activation times τ of cardiac
tissue.
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Figure 4.18: The rescaled minimum radius Rmin/λ of a circular obstacle which is
sufficient to depolarize the tissue at its boundary by φ0 when an electric field E is
applied. For the elecric field denoted by the red line, only obstacles with the sizes
marked in green will be sufficiently depolarized to emit a secondary wave.
4.6.1.1 Optical Mapping of Cardiac Electrical Activity
Optical mapping is an experimental technique developed to observe the change of (mostly
cellular) states in tissue through the use of dyes which change their optical characteristics
depending on the properties to be examined. Typically used are fluorescent dyes whose
emission wavelengths are sensitive to either ion concentrations (such as fluo-4 [85, 86],
which reacts on the intracellular Ca2+ concentration) or the membrane potential (for
example di-4-ANEPPS [87, 88]).
In our experiments, we used the membrane potential sensitive dye di-4-ANEPPS, which
attaches preferentially to lipid bilayer membranes, to measure activation times and to
monitor the tissue’s electrical activity during sinus rhythm, fibrillation and defibrillation
attempts. di-4-ANEPPS is excited by blue and green light around 470 nm and emits
around 630 nm [88, 89]. In response to depolarization of the cell, the fluorescence is
decreased and the emission spectrum is slightly red-shifted, which allows to reconstruct
the activation to be reconstructed from optical recordings.
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4.6.1.2 The Experimental Setup of Optical Cardiac Activation Time Mea-
surements
Optical mapping for activation maps was performed by Philip Bittihn, Flavio Fenton,
Stefan Luther and Amgad Squires [45]. Atrial (n = 5) and ventricular (n = 7) wedge
preparations of beagle dog hearts were cannulated through the coronary arteries and
perfused with normal Tyrode solution (at 50-80mmHg, 37.0(5) ◦C) bubbled with carbo-
gen (5%CO2, 95%O2). The tissue was immobilized by administration of blebbistatin, a
myosin II inhibiting excitation-contraction decoupler (approximately 7 µmol) and stained
with a bolus of di-4-ANEPPS at a concentration of 10 µmolL .
The optical setup was illuminated by LEDs (Luxeon, maximum power 5W, peak wave-
length 530 nm). The tissue was placed horizontally into a glass dish which allowed
imaging from above and below (endo- and epicardium) simultaneously.
High-speed EMCCD cameras (Cascade 128+ with 128×128 pixels, 16bit, Photomet-
rics, USA) fitted with low pass filters at 610 nm were used to record the electrical tissue
activity, controlling and recording of the signals was done with a custom-written pro-
gram10.
To measure the tissue activation times’ dependence on the strength of applied electric
fields, two stainless steel mesh electrodes (approximately 2×4 cm) were placed into the
Tyrode bath at opposite sides of the tissue, at a distance of about 12 cm. A custom
program written in LabView (National Instruments, USA) produced pulses which were
amplified by a high-power amplifier (BOP 100-4M, up to ±100V and ±4A, Kepco,
USA) and delivered to the electrodes. For initially quiescent tissue, series of such pulses
with increasing field strengths allowed to measure the tissue’s response.
We described this setup and the results of the experiments in Luther et al. [45], where
additional details, mostly pertaining to LEAP efficiency experiments, are given.
4.6.1.3 Optical Mapping Image Analysis
In optical mapping with voltage sensitive dyes, the change in amplitude in the optical
signal due to the depolarization of the cardiac tissue is much smaller (typically a few per-
cents) than the naturally occuring spatial variance (can be several orders of magnitude,
caused partly by the structure of the epi- and endocardium and partly by inhomogeneous
staining and lighting of the tissue). To overcome this obstacle, the raw data needs to be
processed before measurements of activated areas and activation times can take place.
10MultiRecorder, written mainly by Johannes Schröder-Schetelig
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Figure 4.19: A single frame from an optical mapping experiment (intact dog heart)
during normal sinus rhythm. For this image, the long time median was subtracted for
each pixel. The approximate silhouette of the heart is given in blue, the wave front is
delineated in red. The pixel intensity values along the white line are shown in yellow,
excited tissue corresponds to darker values. Noise artifacts are still clearly visible, the
only preprocessing for this image was to subtract the temporal median from each pixel.
As described in Luther et al. [45] and in more detail in Bittihn [82], the following
processing steps were performed in order to obtain the activation times:
• A spatial and temporal box filter (5 pixel2 × 5 pixel2, 3 frames) was applied to the
data to remove noise.
• Each pixel’s time series was normalized locally with respect to its minimum and
maximum onto the range [0, 1].
• A simple threshold, typically at 0.5, was applied to classify the pixels’ states as
active or inactive.
• To remove erroneous activation detection due to noise, only those pixels counted
as active (normalized intensity below the threshold) where the average of the next
10 frames also was below the threshold.
• Only pixels whose intensity changes were higher than the noise level and who were
located within one heart chamber (e.g. the right atrium in figure 4.20) were taken
into account.
• Under these transformations, the activation time T (x) for each pixel x is the first
time when its state changed from inactive to active.
Figure 4.20 shows an activation map obtained with this method, where the time between
pulse delivery and activation of each tissue pixel is shown graphically over an unprocessed
image taken by the camera.
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Figure 4.20: The activation map of an piece of atrial/ventricular canine dog heart,
under an external electric field of approximately 0.22 Vcm . Overlayed over the original
grayscale image of the tissue are the color coded times (after onset of the stimulating
pulse) at which the tissue became activated. Image courtesy of Philip Bittihn [82]
Figure 4.21: Activation times in the canine heart under external electric fields. The
required time to activate the whole tissue decreases with increasing field strength, note
that the temporal resolution here is limited by the image acquisition rate of approxi-
mately 2ms/frame. Images courtesy of Philip Bittihn [82]
Following this calculation of activation times for each single pixel, we obtained the
activation time τ for a bulk volume as follows. For each applied pulse of field strength
E, the activation time τ(E) was defined as the time between the activation of 1 and
99% of the tissue [45, 82].
4.6.1.4 Activation Times in Cardiac Tissue
As expected, the activation time decreases with increasing field strength, as can be seen
in figure 4.21, where the activation times are plotted against the field strength, for atrial
and ventricular preparations. Common to all the measured activation time curves τ(E)
is an apparent power law behavior:
τ(E) ∝ Eβ with β < 0 (4.17)
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4.6.2 Linking Times and Sizes
Although others [62] have shown how certain vascular features are related via their
scaling exponents (see also section 4.2.1 on p. 28), there have been no statements about
the sizes or activation times before. Nevertheless it seems reasonable that there should
at least be a prediction about the exact relation between β and α (the exponent in
Pr(r) ∝ rα). After all, the density of blood vessels (or heterogeneities) of a given
size is not only governed by a power law relation as shown in section 5.1.1, but via
equation (4.6) it also influences the number of wave sources and therefore (with (4.16))
the activation time.
Following the arguments laid out in Luther et al. [45] and Bittihn [82], let us assume
sufficiently homogeneously distributed heterogeneities of size r in the tissue, whose size
distribution follows the power law
Pr(r) ∝ rα (4.18)
with α < −1 (4.19)
and which act as obstacles in the sense of section 4.1.1. It makes sense to assume that
these heterogeneities are rather small so the assumption about homogeneous distribution
is most likely true. Since for small obstacle sizes according to (4.6) the electric field




, (A.3 from the appendix.)
the density ρ ≡ NV of wave emitting heterogeneities (WEHs) in the tissue should be:
ρ(E) = ρ (Rmin(E)) ≡
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Now applying this result to the activation time dimensional argument (4.16) yields for
a physical tissue dimension D:





together with τ(E) ∝ Eβ (from 4.17) (4.23)
=⇒ β = α+ 1
D
(4.24)
Using equations (4.21) and (4.24), it is possible to transfer the size statistics into acti-
vation times and vice versa. This also applies to the formulation in terms of power law













5.1 Size Distributions of Blood Vessels
5.1.1 Canine Blood Vessel Size Distributions
The identified vessel sizes in the examined dog hearts ranged from the order of the
voxel resolution (approximately 50 µm) to the size of the largest artery present in the
volume or the catheter, when it could not be completely removed. Between these two
extremes, the distribution of vessel sizes apparently follows a power law, as is shown in
two examples in figure 5.1. Only towards very large sizes, one can see a deviation due
to finite sample sizes, the largest artery or the catheter become very prominent. Apart
from this artifact, the sizes show a consistent behavior over the whole expected range.
The size distributions for all examined heart tissues can be found in detail in the ap-
pendix, in section B.1.
For all analyzed scans, I fitted a power law curve Pr(r) = a · rα to the data, using a
least-squares algorithm implemented in the graphical data analysis tool Grace [90]. The
obtained exponents α are given in detail in table 5.1 and plotted as box plots in figure 5.2.
In this series of experiments, no significant difference between the exponents in canine
atria and ventricles can be found (according to Welch’s t test, the null hypothesis of
equal means can explain the results with p = 0.83).
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(a) canine atrium (b) canine ventricle
(c) atria: µCT projection (d) ventricle: µCT projection
Figure 5.1: Vascular size distributions in dog hearts: Overlayed over the raw radius
counts ((a) and (b)) are the color-coded positions of the detected blood vessels in a
maximum intensity projection (MIP). The power law of the size distributions is clearly
visible in the expected range. A line representing the fitted power law exponent is
overlayed in both plots. For comparison, (c) and (d) show a MIP of the µCT data that
was used for the size reconstructions. Figure first published in [45].
Preparation α ± std. error
#1 -2.80 ± 0.23
#2 -2.74 ± 0.41
#3 -2.76 ± 0.17
#4 -2.67 ± 0.15
#5 -2.79 ± 0.25
average -2.74 ± 0.05
(a) canine atria
Preparation α ± std. error
#1 -2.49 ± 0.11
#2 -2.73 ± 0.10
#3 -3.09 ± 0.13
average -2.75 ± 0.30
(b) canine ventricles
Table 5.1: Exponents for the power law scalings of cardiac blood vessel size distribu-
tions in adult beagle dogs.
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α Figure 5.2: Box plot of the scal-
ing exponents α for canine atria
(left, N = 5) and ventricles (right,
N = 3). The boxes mark the
quartiles, the thick lines indicate
the median of each group. Ac-
cording to this analysis, the scal-
ing exponents for ventricles and
atria are not significantly different
(p > 0.5).
5.1.2 Porcine Blood Vessel Size Distributions
Although the voxel resolution of the reconstructed pig heart volumes was 60 µm/voxel,
the edge response function of the µCT had, depending on the exact scanning setup,
a width of around 200 µm for an intensity rise from 10 to 90% full intensity. This
corresponds well to the smallest detected vessel sizes of approximately 100 µm in this
sample.
As with the dog hearts, the pig vessel sizes were analyzed and a power law distribution
Pr(r) ∝ rα was fitted to the data (from the maximum to the minimum before the last
peak), a typical result for the size distribution is shown in figure 5.3.
The exponents α which obtained from these examinations (detailed distributions are
plotted in the appendix, section B.1.2) are as follows:
Preparation α ± std. error
#1 -2.54 ± 0.34
#2 -2.88 ± 0.15
#3 -2.94 ± 0.22
#4 -3.91 ± 0.33
#5 -4.63 ± 0.12
#6 -3.79 ± 0.28
#7 -2.86 ± 0.19
average -3.47 ± 0.76
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)2.88. The peak around 0.8mm corresponds to the largest arterial
branch, the RCA. The voxel resolution of the µCT reconstruction was 60 µm.
These exponents show higher variations compared to the ones yielded for the dog hearts,
which may be because the heart were prepared longer after the experiment or owing to
the different contrast agent.
5.1.3 Vascular Size Distributions from Other Sources
I applied (4.13) to the numbers for the RCA, LAD and LCx1 arterial branches published
in Kassab et al. [65, tables 1–3 and 9]. The obtained size distributions are shown in





The original data was obtained from polymer corrosion casts (larger vessel diameters)
and extrapolated from histological slices (smaller diameters). The exponents α were
fitted over the whole range, α2 only over the larger vessels.
These numbers should be taken with a grain of salt, though, the assumption that tak-
ing the mean lengths and diameters returns representative results may turn out to be
1right coronary artery, left anterior descending and left circumflex
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Figure 5.4: Size scaling in pig coronary arteries from vascular morphometric data as
published in [65]. Each data point corresponds to one hierarchical vessel order, starting
with order 1 from the left. Note how the error bars allow for a wide range of possible
power law exponents α which would be consistent with this data. Below order 5–6
(r < 1× 10−1 mm), the data was sampled mostly from histological slices, higher orders
come mainly from macroscopic polymer corrosion casts of the vasculature. Colors and
symbols denote for which part of the vasculature the measurements were made: Black
circle (): LAD, red square (): LCx, cyan diamond (_): RCA.
wrong. The large uncertainties associated with the original data (see the error bars in
figure 5.4) are caused by three factors: The size of vessel elements of the same order
varies considerably, the number of elements in an order is only extrapolated from small
tissue samples for smaller orders, and the two different measurement methods (corrosion
casts and histological slices) may introduce an additional bias. Therefore, fitting a power
law distribution to only the larger sizes (orders 7–10) results in the steeper exponents
α2 from the table above.
5.1.4 Comparison of Vascular Size Distributions of Different Origin
Figure 5.5 shows the distribution of the size scaling in pig and in dog hearts (from
table 5.1) and the values α2 calculated from independent branch scaling values in the
literature. αpig and αdog seem to be different, but their means do not differ statistically
significantly, possibly due to the small sample sizes.
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Figure 5.5: Box plot of the
size exponents in porcine and
canine hearts. The three sin-
gle values around −1 are the
α2 as described in section
5.1.3, they are significantly
different from the ones mea-
sured directly from µCT data
(p = 0.0001). Although the
α distribution of pig and dog
hearts are different, this dif-
ference is not statistically sig-
















5.2.0 Activation Time Exponents
Philip Bittihn [45, 82] analyzed the optical mapping data of dog hearts to yield ac-
tivation times as a function of the applied field strength, τ(E). Least-squares fits of
equation (4.17) to this data yielded exponents β with generally small variations as listed
in table 5.2 and figure 5.6. As the vascular size distribution exponents, the exponents
from these data sets do not show a significant difference between atria and ventricles.
5.2.1 Size Distributions Linked to Activation Times
Applying the power law relations from section 4.6.2 to the measured data yields fig-
ure 5.7, with D = 3 for ventricular and D = 2 for atrial data (for a sparse enough
distribution of WEHs, the atrial myocardium is thin enough to be considered essen-
tially two-dimensional). When the power law relations re applied to the exponents from
table 5.1, we obtain the following predicted exponents, which are within one standard
error of the measured values from table 5.2:
Preparation α predicted β measured β
canine atria (D = 2) −2.74± 0.05 −0.87± 0.025 −0.75± 0.18
canine ventricles (D = 3) −2.75± 0.30 −0.58± 0.10 −0.81± 0.23
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Figure 5.6: Box plot of the activa-
tion time scaling exponents β for ca-
nine atria (left, N = 23) and ventri-
cles (right, N = 17). The boxes mark
the quartiles, the thick lines indicate
the median of each group. According
to this analysis, the scaling exponents
for ventricles and atria are not signifi-































Figure 5.7: Vascular size distributions and activation times in dog atria, transformed
using (4.25). The green symbols stand for the data which originates in the size distri-
bution (upper left panel) and is being transformed into WEH source densities (lower
left) and activation times (lower right). The original activation time data, reversely,
is represented by the blue symbols and can be transformed into a corresponding size
distribution. This figure was first published in [45].
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Preparation β (mean ± std. error)
#1 -0.76 ± 0.09
#1 -0.78 ± 0.06
#2 -0.35 ± 0.10
#2 -0.97 ± 0.10
#3 -1.08 ± 0.41
#4 -0.92 ± 0.06
#4 -0.54 ± 0.08
#4 -0.94 ± 0.07
#4 -0.68 ± 0.08
#4 -0.90 ± 0.07
#4 -0.55 ± 0.07
#5 -0.67 ± 0.08
#5 -0.55 ± 0.05
#5 -0.81 ± 0.12
#5 -0.67 ± 0.07
#5 -0.83 ± 0.09
#5 -0.64 ± 0.03
#6 -0.99 ± 0.07
#6 -0.53 ± 0.09
#6 -0.87 ± 0.10
#6 -0.67 ± 0.09
#6 -0.80 ± 0.08
#6 -0.64 ± 0.10
average -0.75 ± 0.18
(a) canine atria
Preparation β (mean ± std. error)
#1 -0.80 ± 0.06
#1 -1.38 ± 0.09
#1 -0.45 ± 0.11
#1 -0.98 ± 0.10
#2 -0.77 ± 0.06
#2 -0.81 ± 0.05
#2 -0.95 ± 0.08
#2 -0.80 ± 0.08
#2 -1.01 ± 0.08
#2 -1.12 ± 0.10
#3 -0.89 ± 0.05
#3 -0.76 ± 0.05
#3 -0.71 ± 0.05
#3 -0.75 ± 0.03
#3 -0.58 ± 0.03
#3 -0.56 ± 0.04
#3 -0.53 ± 0.03
average -0.81 ± 0.23
(b) canine ventricles
Table 5.2: Measured exponents and weighted averages for the power law exponent β of
cardiac activation times τ(E) ∝ E−β in adult beagle dogs. For each preparation, several
activation time measurements were made and their weighted average was calculated.
Data was first published in [45].
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Chapter 6
In Vivo LEAP Experiments
In clinical application, life-threatening ventricular fibrillation (VF) is usually treated
with electrical shocks resulting in field strengths of over 5 Vcm (if delivered externally,
this means energies of 150 J which at typically 15ms corresponds to over 20A at about
500V [91]). For patients at an increased risk of ventricular fibrillation, implantable
cardioverter-defibrillators (ICD) are a common measure, with over 200 000 new implants
taken place in 2009 alone [92]. An ICD typically delivers shocks with energies of about
40 J in the case of detected VF, which is considerably less than for external defibrillation
but can nevertheless lead to traumatic pain in the case of malfunctions [38] (when the
patient is still conscious). Because of its potential life-saving abilities, there is currently
no alternative to ICDs, so lower energy alternatives such as LEAP (see chapter 3 for an
introduction) are an area of interest. In order to advance these new methods towards
clinical applicability, it is necessary to test them in models that are as close to human
use cases as possible.
6.1 Previous Studies
After the first theoretical proposals [47], LEAP has been experimentally tested in nu-
merous systems: In cell cultures of cardiomyocytes [93], in perfused rabbit hearts [94]
and dog heart tissue preparations [45] and in vivo in dog hearts [45].
In [93] Pumir et al. argue that for neonatal rat myocyte cell cultures, as predicted in
[47], the required energy to unpin a pinned spiral from a non-conducting heterogeneity
should be a factor of 500 smaller than the energy for complete defibrillation.
We showed in [45] that in dog heart preparations it is possible to decrease the energy
required to terminate VF to 15% of the single shock defibrillation energy. For atrial
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fibrillation (AF), the necessary energy was only 10%, both in ex vivo preparations and
in in vivo experiments.
6.2 Towards Clinical Application
6.2.1 Experimental Criteria
In order to further develop LEAP towards clinical application, model systems need to
be as close to the human organism as possible. This includes:
Physiological Environment Although many insights into the mechanisms of cardiac
activation, pathological excitation patterns and termination of e.g. fibrillation can
be gained through experiments with cell cultures or ex vivo preparations, these
methods always include a certain level of abstraction from living organisms. Only
with in vivo models there is a realistic chance of capturing all relevant properties
and responses to defibrillation attempts.
Scaling In order to develop fibrillatory excitation patterns comparable to the human
heart, the ratio of the excitable substrate’s size to the typical excitation wave
lengths should be about the same as in human hearts. In general, Strain and
Greenside [95] showed than turbulent spatio-temporal behavior requires a mini-
mum medium size. In too small media such as mouse or rabbit hearts, fibrillatory
patterns are enabled through administration of drugs which affect the action po-
tential. For example, acetylcholine is commonly used, since it shortens the action
potential [96] and thus promotes arrhythmia.
Field geometry The most relevant potential application for LEAP would be in ICDs
(implantable cardioverter-defibrillators). The common implementation of one intra-
ventricular coil as one electrode and the case of the ICD itself, implanted below
the pectoralis major muscle, as the other electrode, leads to a very specific field
geometry which is not reproduced in most experiments so far. In most numeri-
cal simulations, cell culture experiments [97], tissue preparations and even many
in vivo experiments [45] though, the electric field is mostly homogeneous. This
difference must be taken into account to compare results.
Species Results obtained for a single species only may not giove the full picture yet.
E.g. the Purkinje fiber network is different in pigs compared to humans [98] and
the different orientation of the heart relative to the chest may play a role in VF
termination through external shocks. Deviating shapes of action potentials in
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other species indicate differences on the cellular level and in the process of tur-
bulent activity, which may also make the transfer from animal models to humans
challenging.
6.2.2 Clinically Relevant Animal Models for LEAP
Previous experiments assessing the viability and efficiency of LEAP in whole hearts only
included animals up to (regarding the size) rabbit [94]. In dog hearts, LEAP was tested
only in atria or in isolated tissue, which changes both the size of the relevant medium and
also potentially its topology. To evaluate LEAP in models closer to clinical application
in humans, we conducted a series of in vivo experiments with pigs.
The hearts of young or small pigs are comparable in size to human hearts (approxi-
mately 210 g for pig hearts [99] compared to about 300 g in humans [27]), as well as the
dimensions of the thorax, which allowed us to test electric configurations similar to the
ones used in ICD patients. The results showed that the required energy for defibrillation
was about the same as applied on humans.
We used pigs of two races for our LEAP experiments: juvenile male German Landrace
animals and adult Göttingen minipigs. The pigs of both races were comparable in body
weight in heart size. We expected this diversity to highlight possible biasing effects due
to age, while still retaining a model that is comparable to adult humans.
Since the previous most successful attempts at testing LEAP in experiments were done
using beagle dogs (though only AF in vivo and heart slices ex vivo), we decided to
continue with that animal model and do in vivo VF and whole heart ex vivo experiments.
Here the in vivo experiments were done with with epicardial mesh electrodes in an open
chest setting instead of ICD catheter and can.
6.3 The Experimental Setup
The experiments were set up so that a number of constraints would be fulfilled:
• Reproducible inducibility of fibrillation with very low energies.
• Reliable termination of VF even if LEAP fails in order to minimize the duration
of ischemia for the heart.
• Manually controllable and reproducible delivery of shocks to the heart, either mul-
tiple shocks for LEAP or single shocks for comparison with classical defibrillation.
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Figure 6.1: Schematic of four Kepco power amplifiers connected in series and parallel,
for defibrillation of the heart in the experiment (on the right). The analog BOP 100-4M
deliver up to 100V and 4A, while the digital BOP 100-10MG can support currents up
to 10A at the same voltage. Together they can defibrillate with 200V × 14A (power
diagram in the upper right corner). In this schematic, blue lines depict the control
hierarchy. The computer controls the amplifier À’s output, which in turn passes on its
current state to Á through Ã for voltage and current amplification, respectively. The
amplifiers are connected by fail-safe emergency shut-off signal lines (red) so that failure
in one device shuts off the others as well. The current and voltage of the devices is
continuously monitored by the computer (green lines). Further explanations are given
in the text below.
The single shocks should be strong enough (i.e. be above the defibrillation thresh-
old (DFT)) to reliably defibrillate the heart.
• Ability to stimulate the heart should it go into asystole after successful defibrilla-
tion.
• Acquisition of the relevant electrophysiological data as collected by ICDs and be-
yond, such as ECG, intraventricular action potential and defibrillation current.
• Controlled life support for the animal to attain reproducible results over the course
of the experiment and to minimize the effects of the unavoidable periods of relative
ischemia during VF.
6.3.1 Prototype LEAP Devices
According to the specific needs, we used two distinct kinds of power supplies for de-
fibrillation. Common to both are the “connections” to the animal mimicking clinical
application.
66
6 In Vivo LEAP Experiments 6.3. The Experimental Setup
6.3.1.1 Power Amplifiers for Lower Energy Requirements and Higher Flex-
ibility
In the open chest experiments we conducted on beagle dogs, the required peak power
was low enough that commercially available high-power amplifiers were sufficient. We
used up to four amplifiers (two BOP 100-4M, 400W, two BOP 100-10MG, 1 kW, Kepco
Inc., USA) together delivering a maximum power of 2800W, or 200V× 14A. Although
the amplifiers themselves were available off the shelf, connecting them in series and in
parallel as shown in figure 6.1 still needed major adjustments. Specifically, this included:
Synchronization The amplifiers can act either as current or as voltage sources (or
sinks, depending on the voltage across it load outputs). In order to deliver the
needed current to the heart, all four devices must work together, and especially
their polarity must be matching lest they act as a short-circuit with positive feed-
back. The 1 kW amplifier marked with À in figure 6.1 acted as the primary master
to the other amplifiers. It was controlled directly through a DA/AD converter
by a custom LabView program (see figure 6.8 for a screenshot of the defibrillator
control software). Information about the voltage across its load outputs was fed
into the primary slave Á, an identical device which effectively doubled the voltage.
To ensure that no current was flowing circularly through the four amplifiers, the
secondary master Â was configured to act as a current source providing 40% of
the current flowing through À. This 400W amplifier in turn worked in series with
another identical device, the secondary slave Ã in voltage mode.
This configuration guaranteed that all amplifiers worked synchronously at the same
level of their respective maximum power. The control flow is shown with blue
arrows between the amplifiers in the figure.
Safety Because the amplifiers were set to reach their given target voltage/current with
all the power available, one faulty device might cause a cascade of potentially
harmful or damaging failures in the others as well. Therefore we connected all
amplifiers with a chain of fail-safe, partly custom-built shut-off triggers, denoted
with red lines in figure 6.1. In the case of one device detecting a malfunction and
shutting itself off, all other devices would switch themselves off immediately as
well.
Recording In order to reliably record the energy which is actually delivered to the
heart, the output current and voltage of the involved amplifiers was fed back
into the control and measurement computer, shown as green lines in the setup
schematic.
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Figure 6.2: The power amplifiers in a
19 " rack. Correspondence of single ampli-
fier units to figure 6.1 is denoted by the
numbers À. . .Ã.
This setup allowed us to adjust e.g. the waveform of the LEAP pulses arbitrarily and
also to deliver an arbitrary number of pulses, without delays for recharging of capacitors.
The rise time from 0 to 100V was less than 1ms, fast enough compared to typical action
potential durations on the order of 100ms. One practical requirement was that the whole
setup be mobile in order to quickly set up the experiment in the operation room and
move all devices out again after finishing the experiment. We mounted the amplifiers
onto a standard wheeled 19 " rack (figure 6.2). In the course of the experiments, it turned
out that the required power was so low that the amplifier system could be reduced to
just the two digital 1 kW devices (À and Á).
6.3.1.2 A Custom-Built Defibrillator
The peak power which could be delivered by the power amplifier assembly described in
the last section was sufficient for the open-chest experiments with patch electrodes. For
the experiments with catheter shock electrodes and ICD case however, larger energies
per pulse were necessary.
To fulfill these increased requirements across one or many user-defined shocks, we had
a custom experimental defibrillator built at and in collaboration with the electronics
workshop at the Third Institute of Physics at the University of Göttingen. According to
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Figure 6.3: The experimental LEAP defibrillator. Top view of the internal boards: À
The high voltage transformer used to charge the capacitors and the control logic board.
Á Five capacitor banks for up to 10 high voltage pulses. Â The bridge board to route
the capacitors to the experiment connector and to switch polarity if required. Ã Front
panel with high voltage connector (left), and control/sensing links and charge display
(middle panel)
our specifications regarding voltage, energy and number of pulses, Dr. Lautscham and
Mr. Ebrecht at the workshop developed a LEAP prototype defibrillator.
This defibrillator can deliver up to ten monophasic shocks with 1000V peak voltage and
78 J per pulse, corresponding to five symmetric biphasic shocks of over 150 J each.
In order to be able to deliver the required high peak power, our defibrillator is based
on the same principle as commercial defibrillators, using charged capacitors. Here, the
defibrillator (see figure 6.3 for pictures) contains ten capacitor banks of 155 µF which
are charged through a high voltage power supply (1C24-P30, Ultravolt, USA). Charging
takes approximately 40 s from a fully discharged state to the maximum of 1000V. The
maximum voltage can be set either manually on the front panel or remotely via an analog
voltage input (stepped up by a factor of 200). Each capacitor bank (see figure 6.3 for an
interior view) can be discharged separately through a digital input to the defibrillator,
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Figure 6.4: Overview schematic diagram of the experimental LEAP defibrillator,
showing control of the output bridge and capacitor charge/discharge control. Schematic
by Ebrecht/Lautscham
the polarity can be chosen as required and switched during or between pulses. For safety
reasons, the capacitors automatically discharge upon shut-down or power loss.
The defibrillator was accessed by a DA/AD converter (NI USB-6259 BNC, National In-
struments, USA) which was controlled by a PC running self-written LabView (National
Instruments, USA) control software, similar to the power amplifier described in the pre-
vious section. This software allowed us to monitor one arbitrarily chosen bioelectric
signal, for example the ECG and, if deemed necessary, to automatically calculate the
temporal defibrillation parameters from its time series.
At the same time, data from (electro)physiological sensors and the defibrillator current
and voltage was recorded for simultaneous and later analysis (figure 6.5). Using for exam-
ple the peak values of current and voltage of the last shocks to calculate the impedance,
our software can autonomously choose the correct voltage for a desired energy.
In the example of figure 6.5, the impedance was 50 W, the peak current at the initial volt-
age of 399V was 8A. With less than one quarter of its maximum power, the custom-built
defibrillator successfully defibrillated the heart (pig, 2011-12-12) where the combination
of four power amplifiers would have failed. As can be seen in the plot, about two seconds
after the shock, the blood shows a significant level of oxygen again.
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Figure 6.5: Time series of a successful single pulse defibrillation. Shown are the
defibrillator current (light blue, dark blue in the inset), one ECG lead, and the blood
oxygen saturation. The inset shows the exponentially decaying current during the two
phases of the shock.
6.3.2 Electrical Connection to the Heart
6.3.2.1 A Temporarily Implanted Defibrillator
To be as close to clinical application as possible, we used commercially available ICD
catheters (Sprint Quattro, Medtronic, USA) which were inserted into the right ventricle
(RV) of the animal. The electrically relevant part consists of a shocking coil and two
electrodes for recording and low-energy stimulation, see also figure 6.6a.
Figure 6.6b shows the other electrode, a stainless steel replacement for the ICD can which
was embedded under the left pectoralis major muscle. This guaranteed with little effort
that the electric field would be as similar to the one in humans with ICDs as possible.
Both parts, the catheter and the ICD phantom were safely connected to the defibrillator
devices, if necessary, the connection could be switched to a backup defibrillator within
a few seconds.
6.3.2.2 Epicardial Mesh Electrodes
Similarly to the experiments in [45], we decided to use mesh electrodes on the epicardium
for the open chest dog experiments. Additionally to better comparability to previous
studies, we expected advantages with respect to the field geometry and absolute energy
requirements. We used flexible wire mesh (stainless steel) patches of 10 cm2 × 10 cm2 to
which we welded solderable contacts of about 3 to 4 cm width (see figure 6.7 and the
electrodes in use in figure 6.11). In-situ, the mesh was cut with common scissors so as
to fit to the heart’s shape.
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(a) An ICD catheter of the type used in the in vivo experiments. The recording and defibrillation
equipment is connected at À. Note the two small electrodes at the tip of the catheter Â, the
corkscrew emerges from the tip and fastens the catheter tip into the tissue. The coil Á serves as
a high surface area electrode during defibrillation shocks.
(b) The ICD phantom used in the ICD experiments. Its size and shape
(55mm× 50mm× 15mm) correspond to ICD cans that are routinely implanted to hu-
man patients.
Figure 6.6
Figure 6.7: Mesh electrodes used in the open chest experiments. The shape was
individually adapted by cutting the mesh with normal scissors.
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6.3.3 Physiological Measurement Recording
During the experiment, we recorded data from electrophysiological and other medically
relevant sources, for two-fold purposes: It enabled us to adapt the experimental settings
in the course of the experiment and allows for detailed analysis of possible dynamical
effect of success or failure of defibrillation afterwards.
All signals were captured at 2 kHz with commercial hardware modules (Biopac, USA)
and recorded with the software package Acqknowledge (Biopac, USA). In all experi-
ments, we recorded the following signals:
• Three-lead ECG, taken from the upper right and left chest and near the left hip
joint. Due to the different orientation of the heart in quadrupeds (the apex is
oriented towards the sternum), the recorded signal differs from the well-known
ECG in humans.
• Action-potential recordings from the tip of the intraventricular catheter. The
potential difference across the two small electrodes on the catheter (see figure 6.6a)
gives a reliable signal about the electrical activity in the vicinity of the catheter.
This is also the configuration which is used by commercial ICDs to monitor and
record the electrical activity in the heart.
The action potential and ECG signals were amplified and directly fed into the
Biopac AD converter. To prevent potential risks for users and the hardware mod-
ules during high voltage events, the leads were fitted with an overvoltage protec-
tion.
• Blood oxygen saturation (SpO2) and exhalation CO2 concentration were measured
at the tongue or ear and the respiration apparatus, respectively. During fibrilla-
tion, these easily accessible vital parameters give an indication how ischemic the
organism is.
• Current through and voltage across the defibrillator output, whether it be our
custom-built prototype or the high power amplifiers. During defibrillation at-
tempts, only the shock voltage is set, while the impedance of the system is gen-
erally unknown. To obtain the delivered energy, the exact values of current and
voltage over time are necessary.
During the experiment, we used the electrophysiological recordings (ECG and local
action potential at the catheter on the endocardium) to estimate the current dominant
frequency of the fibrillation and to decide the pacing frequency of the next defibrillation
attempt (see figure 6.8 for a screenshot of the acquisition software).
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The time-resolved time series of current and, depending on the configuration, voltage,
allowed to calculate the delivered energy per pulse. Generally we calculated the energy
by first computing the setup’s impedance R as the ratio of maximum voltage and current.
With this information, the energy E for a pulse could be calculated by
E =
∫
R · I(t)2dt. (6.1)
6.3.4 The Animal Operation Room Setup
The operation room setup was equivalent for the in vivo experiments for pigs and dogs.
The setup was designed to provide all necessary means required by animal welfare guide-
lines and for a maximum efficiency in the experiment. The animals were held in anes-
thesia by artificial respiration with pure O2 supplemented with 1–2% isoflurane. The
artificial respiration guaranteed a minimum of ischemia during the periods of reduced
or suppressed cardiac pumping. The recorded signals mentioned in the previous section
were continuously monitored.
In addition to our experimental defibrillator / power amplifiers, we had a commercial
defibrillator implant support device (Medtronic DISD 5358, Medtronic, USA) available
in standby as a backup defibrillator system to minimize the fibrillatory period. As a
secondary backup, an external defibrillator with paddles was available in the OR for
cases when the experimental defibrillator or the first backup failed, e.g. because the
catheter was in an unfavorable position.
For the pig in vivo experiments, we had a mobile fluoroscopic X-ray system available
to control the correct positioning of the ICD catheter inside the heart. This was not
necessary for the dog open chest experiments, since there the catheter’s position could
be seen directly.
6.4 Experimental Procedure
For the in vivo pig LEAP experiments, we used N = 9 juvenile male domestic pigs (Sus
scrofa domesticus, German Landrace) and N = 5 adult male Göttingen Minipigs. We
chose the pigs’ ages so that irrespective of their race, they weighed approximately 30 kg
(mean±s.d. 35± 11 kg). The beagle dogs were about 14 months (mean±s.d. 14.3± 1.7
months) old and weighed about 10 kg (mean±s.d. 9.7± 1.3 kg). All animal handling and
74
6 In Vivo LEAP Experiments 6.4. Experimental Procedure
(a) Data acquisition software
(b) Defibrillator control software
Figure 6.8: Screenshots of the software used for data acquisition (Acqknowledge,
Biopac, USA) and defibrillator control. (a) The relevant recorded time series during
defibrillation with LEAP. 5 pulses terminate the fibrillation with 99V, single pulses
with 130V failed to defibrillate before and after this event. The two ECG traces (green
and magenta) and the blood oxygen saturation (red) indicate successful defibrillation.
(b) The control software front panel (left) and part of its internal structure (right),
written in LabView (National Instruments, USA). With this custom-written software,
we could control the number of pulses, voltage, pacing period, polarity, pulse duration
and pulse shape and switch between mono- and biphasic pulses.
the experimental procedures were approved by the responsible authorities (the Nieder-
sächsisches Landesamt für Verbraucherschutz und Lebensmittelsicherheit (LAVES) for
the pig experiments and the Institutional Animal Care and Use Committee (IACUC) at
Cornell University for the dogs) and experienced veterinarians were present during the
experiments to supervise the procedures and to ensure the animal was free of pain at all
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Figure 6.9: Fluoroscopic ventral view of an ICD catheter in the RV of a pig heart.
Right, left, anterior and posterior directions are marked on the picture. Note the two
sensing/stimulating electrodes at the tip of the catheter. The slight double image of
the catheter coil is due to the heart’s beating during exposure.
times.
6.4.1 Pre-Fibrillation
The animals were anesthetized with fentanyl and sedated with propofol by the veteri-
narians, intubated and connected to the respirator (100% O2 with 1–2% isoflurane).
Capillary SpO2, the exhaled CO2 concentration and the electrocardiogram were contin-
ually monitored. During the whole experiment, the body temperature was kept constant
at a physiological level with blankets or electric heating.
6.4.1.1 ICD Phantom Implant
In the pigs, an ICD catheter (two sensing/stimulating electrodes at the tip, 1–2 coils for
delivering defibrillation shocks, Medtronic, USA) was inserted via the jugular vein into
the right ventricle (RV). Under fluoroscopic positioning control, its tip was secured at the
endocardium close to the apex by means of a corkscrew-type fastener embedded into the
catheter. After this procedure, the coil was completely inside the RV. For an example
of the final catheter position, comparable to human ICD implants, see the printout of a
fluoroscopic image in figure 6.9.
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Figure 6.10: RV monophasic action potential (MAP) as measured with an ICD
catheter electrode in a pig heart.
Subsequently the ICD case phantom (figure 6.6b) was placed into a pocket under the
pectoralis major m., about 15 cm from the catheter coil. The catheter and the case were
connected to the defibrillator sets and to the monitoring/stimulating modules.
The correct position of the catheter tip was verified by two independent means: the
electric signal should show an undistorted action potential (figure 6.10) and a low pacing
threshold for the stimulating electrodes (around 1V at 0.5ms pulse duration) was verified
(with a Medtronic Analyzer 2290, Medtronic, USA).
6.4.1.2 Open Chest Electrode Application
In the open chest dog experiments, after induction of anesthesia, the thorax was opened
up via sternotomy. The pericardium was incised and epicardial electrodes were attached
to the epicardium. To keep the impedance between the defibrillators and the heart and
the electric field inside the heart as constant as possible in the course of an experiment,
we secured the patch mesh electrodes to the epicardium and filled any remaining gap
with conductive gel. In the course of the experiment, the mesh and gel were kept wet by
adding saline as necessary and before each fibrillation episode. The patches were fixed
to the epicardium either with several sutures or by applying a few drops of commercially




Figure 6.11: Patch mesh electrode in situ secured onto a dog heart in open chest
LEAP experiments. The electrodes in (a) were sutured to the epicardium, the electrodes
in (b) were held in place with common superglue. The orientation of these images is
the same as in figure 6.9.
In order to find the configuration with the lowest energy requirements, we used several
distinct electrode configurations: with an additional ICD catheter electrode inside the
RV and without. We also varied the size of the patches from covering nearly the whole
heart to pieces of about 3 cm diameter.
In all experiments, the ICD catheter was inserted through the opened thorax and the
v. cava superior into the RV.
6.4.1.3 Initial Impedance Measurement
After completing the setup of the high voltage electrodes, the shock impedance was
measured with the implant support device by delivering a 0.2 J test pulse. In case this
pulse would induce an arrhythmia in the heart (it was not synchronized with the ECG),
the same Medtronic device could be used to immediately defibrillate if necessary. This
impedance then served as a scaling factor during the experiment to estimate the shock
energy from the applied voltage and to set the voltage so that a desired energy was
reached.
The measured impedances with catheter-can configurations were in the same range as
for human ICD implants (20 to 100 W [100]); for epicardial patch electrodes, they were
significantly higher, probably due to the fact that since at least one electrode was in the
air, no current could flow around the heart:
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Electrode setting N Impedance mean s.d.
catheter-can (pig) 14 65.8 W 7.2 W
epicardial patch (dog) 6 92.8 W 14.2 W
6.4.2 Defibrillation to Evaluate LEAP Efficiency
The main purpose of the series of experiments was to assess the efficiency of LEAP
compared to single pulse defibrillation, measured as the energy per pulse required to
successfully terminate VF.
The general procedure for all (de)fibrillation episodes was: induction of VF, waiting 10 s
to verify that the VF would not terminate itself, termination of VF within less than
1min after induction, letting the heart and animal recover before the next episode.
We induced fibrillation by stimulating the heart near the apex with the tip of the ICD
catheter for about 3 s with 50Hz and just sufficient voltage to obtain capture (as could
be verified in the ECG traces). Subsequently we waited for 10–15 s to ensure that the
fibrillation was stable.
No more than 20–30 s after effective pumping of the heart stopped (which means that
the VF induction time had to be included), we attempted to terminate the fibrillation,
either with a single defibrillation shock in order to determine the defibrillation threshold
(DFT) or with LEAP (5 pulses of lower energy), varying the energy, wave form or the
pacing frequency’s ratio to the fibrillation’s dominant frequency.
If this attempt failed, we immediately switched the wiring to connect to the commercial
backup defibrillation device and defibrillated the heart with a single biphasic shock of
34 J (for the catheter-can configuration in the pigs) or 10 J (for the patch electrode setup
in the dogs). In nearly all cases of primary failure to defibrillate, the first backup shock
was sufficient to terminate the fibrillation at once. In those cases where the backup
shock failed as well, the external defibrillator was loaded and prepared for discharge. If
during this preparation time further backup shocks by the primary backup defibrillator
did not terminate the arrhythmia, the external defibrillator was discharged as many
times as necessary to get the heart out of fibrillation.
If the heart stayed in asystole for more than a few seconds after fibrillation, we stimulated
it with low voltages at physiological frequencies (about 1 to 2Hz depending on the
species) until normal sinus rhythm set in again.
After each such episode of fibrillation and termination, we waited several minutes to let






































Figure 6.12: Schematic of the in vivo experimental protocol.
on the ECG interpretation of experienced cardiologists who were present during the
experiments, it was mostly about 2 to 3min long. In a few experiments we deliberately
waited considerably longer (7 to 10minutes) to check if the recovery time had any
influence on the DFT.
6.4.2.1 Choosing the Defibrillation Parameters
Our aim was to measure the possible energy gain through LEAP, this gain is always
relative to the energy required for defibrillation by single shocks. Unfortunately there is
no sharp cut-off energy above which defibrillation suddenly happens, but the DFT can
80
6 In Vivo LEAP Experiments 6.4. Experimental Procedure
only be defined in terms of defibrillation success probabilities. To detect possible drifts in
the DFT, we measured it first at the beginning of an experiment and later at least once
every hour. For this we attempted to defibrillate with a single shock at a supposedly
above-threshold energy. If the defibrillation attempt was successful we decreased the
energy by some amount (usually 2 J), otherwise we increased it by the same amount.
This up-down procedure was repeated until the “success barrier” was crossed at least
two times, i.e. until we had gone from successful to unsuccessful and back again or vice
versa.















Table 6.1: Overview over defibrillation shock wave forms.
Additionally to the energy, the wave form also plays a role in determining defibrillation
success, table 6.1 shows an overview over some characteristics of shock pulses. The
following are the parameters we had to choose, some of which only apply to LEAP
pulses, though:
Single Pulse Shape Clinical defibrillators, implanted and external, use capacitors to
deliver a large amount of energy in a short time, just as the custom-built defibril-
lator we used for the pig experiments. In contrast in the dog experiments, we were
able to define arbitrary wave forms, especially square pulses instead of exponen-
tially decaying voltages as in discharging capacitors (first row of table 6.1). We
mostly chose square pulses (second row) because ex vivo experiments showed no
difference between the DFT for both wave forms and with square pulses the same
energy could be delivered with less peak power.
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Mono-/biphasic Instead of discharging the capacitor at once (monophasic pulse, first
column of pictures in table 6.1), it is possible to switch polarity during the discharg-
ing process (biphasic pulse, second column). Since it is widely known that biphasic
shocks have higher probabilities of terminating fibrillation than monophasic shocks
of the same energy [101], we used only biphasic shocks in nearly all experiments.
Wave Symmetry When a single capacitor is used to produce a biphasic pulse, the
second part naturally has lower voltages (second column). We decided mostly
on either discharging another capacitor or setting the voltage symmetrically in the
power amplifiers (third column) in order to deliver a maximum of energy and to be
more independent of the configuration’s impedance, which influences the steepness
of the exponential decay and thus the voltage and power ratios of the two pulse
parts.
Frequency Ratio When pacing with more than one pulse, the temporal coordination
with the fibrillation pattern becomes important. For termination of tachycardia
(ventricular and atrial), local pacing slightly faster than the dominant cycle length
(antitachycardia pacing, ATP) [102, 103] is the preferred method of driving the
heart into a healthy rhythm again. For termination of VF with LEAP which uses
far-field pacing, previous studies have been inconclusive [45] if higher or lower
frequencies compared to fibrillation obtain the best energy gains. Therefore we
investigated broad frequency ranges, from about 0.7 to 1.3 times the dominant
frequency.
Number of Pulses Theory and numerical simulations predict [47, 48] that for LEAP
to succeed in unpinning a pinned spiral wave, the phase of the pulse relative to the
spiral must fall into the unpinning window. Several pulses increase the chance that
one of the pulses falls into the unpinning window and when npulse = f / (f − f ),
the whole phase should be covered (with npulse being the number of pulses and f
and f being the frequencies of the pacing and the pinned spiral, respectively).
This reasoning is not perfect though, since effects like phase resetting as described
in [49] may arise. With frequency differences of up to approximately 20%, we
stayed with npulse = 5 for nearly all experiments, this was also the maximum our
custom-built defibrillator could deliver for biphasic symmetric pulses. We did not
gather meaningful amounts of data for npulse other than 1 or 5.
6.4.3 End of LEAP Experiment
For all in vivo specimen, we continued the experiment as long as technically and ethically
possible. We stopped to do further defibrillation attempts, if the heart showed signs of
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Figure 6.13: Experiment durations and number of defibrillation events for the in vivo
experiments. Times measured from the first to the last defibrillation episode. The two
short pig experiments (bottom left corner) were one where defibrillation failed early
in the experiment (leftmost) and where the catheter detached from the endocardium
(second from the left).
substantial change in behavior, such as:
• much slower recovery after fibrillation events
• difficulties to terminate VF (increased DFT)
• VF would terminate spontaneously or after very low shocks (decreased DFT)
• after professional advice from the veterinarians, e.g. after drop of blood pressure
Usually the experiments lasted for over 2 hours (average for pig experiments: 2.2 h, dog
experiments: 2.6 h), the maximum was 3.4 h (pigs) and 5 h (dogs), respectively. In this
period, we were able to perform on average 35 and 39 defibrillation attempts (see also
figure 6.13).
After the decision to end the in vivo experiment, the animal was prepared for the follow-
ing Langendorff perfusion. We administered sufficient heparin to prevent post-mortem
blood coagulation (400–500 IU/kg) a few minutes before the veterinarians applied a
lethal dose of pentobarbital. After the animal’s death, while still under artifical respi-
ration, we flushed the heart with approximately 500ml of ice cold cardioplegic solution
(high-K, approximately 8mmol, exact composition in section 7.4.1) in order to arrest
the heart in the diastolic state and to preserve it as well as possible for the following ex
vivo experiments.
Subsequently the heart was extracted, with median sternotomy if necessary, submerged
into 0 ◦C cardioplegia solution, with any air removed from the vasculature and stored




Ex Vivo LEAP Experiments
In addition to the in vivo experiments described in the previous chapter, we conducted
two series of ex vivo low energy antifibrillation pacing (LEAP) experiments with pig and
dog hearts. Similar experiments have previously been performed on smaller samples,
either in intact rabbit hearts under Langendorff perfusion [94, 104] or in wedge prepa-
rations of larger hearts (dog hearts, [45]). We continued in this direction in order to fill
the gap between the more controlled environments of in vitro and the more clinically
relevant in vivo experiments.
7.1 Benefits of Ex Vivo Antifibrillation Experiments
Although in vivo studies have advantages such as a naturally realistic physiological em-
bedding and the same configurations of electrical field and current as in clinical appli-
cations, there are a number of undisputed benefits of ex vivo defibrillation experiments.
Besides the ethical and economical advantage of obtaining as much knowledge as possible
from a heart after an in vivo experiment, there are the following points:
7.1.1 A Controlled Environment
In contrast to experiments in living animals, the electric field can be defined compara-
tively freely. The freedom of choosing the electrode configuration allows to study how
the field geometry influences the energy requirements of single pulse defibrillation and
LEAP. Whereas electrode configurations with one intraventricular catheter coil and an
ICD always lead to regions with no or at least negligible fields (according to Walgott
et al. [36], the field on the far side of the heart is only 1/10 as large as on the side
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facing the ICD can), in ex vivo setups the E field can be chosen to be nearly homo-
geneous. Conversely, it is of course also possible to reproduce the E field of in vivo
configurations or to adapt the electrode configuration in order to optimize upcoming in
vivo experiments.
Furthermore, the controlled environment of a perfusion setup minimizes changes in the
experiment over time such as movement of the heart relative to the electrodes and
keeps chemical and physiological changes at a minimum. The continuous perfusion with
oxygenated solutions such as Krebs-Henseleit solution or Tyrode’s solution ensures a
steady supply of oxygen to the tissue, thereby removing the risk of ischemia inherent
to in vivo antifibrillation experiments. Possible adverse effects of long-term fibrillation
itself can not be excluded in this way, but they could be differentiated from effects of
ischemia.
7.1.2 Experimental Efficiency
Without ischemic periods, it is not necessary in perfusion experiments to give backup
shocks should the fibrillation not be terminated immediately after induction. Combined
with the absence of recovery periods between fibrillation episodes, this leads to a much
higher efficiency in terms of defibrillation attempts per time. Whereas in vivo, one
defibrillation attempt required about 4 minutes, in the perfusion setup, the average
time between two attempts was as low as 30 seconds. The defibrillation results show no
difference regarding the long-term behavior of defibrillation energy compared to the in
vivo experiments (chapter 8), so it is a valid assumption that in spite of the different
time scales the results are comparable. For an overview over the ex vivo number of
defibrillation attempts also compare figure 7.6 to figure 6.13.
7.1.3 Contactless Activation Measurement
Major advantages of a perfusion setup are the accessibility of the whole surface of the
heart for experimental measures and the independence of the heart on its pumping
function. With voltage sensitive dyes, the cells’ activation can be measured with high
spatial resolution and without electrical contact. This circumvents the problem that
measuring the low amplitude electrophysiological signals directly is not possible during
shocks. Also the recording amplifiers usually need several seconds after the delivery of
a defibrillation shock to recalibrate themselves to the normal signal level again. Optical
mapping of cardiac excitation does not suffer from these limitations and thus can give
reliable information about success or failure of antifibrillation pacing.
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Additionally the spatial resolution of optical mapping allows more complex analyses
of the heart’s spatio-temporal behavior, e.g. through activation maps under different
electric fields.
7.2 Open Questions
With the ex vivo experiments, we tried to gain insight into the following problems:
7.2.1 Comparability with In Vivo Experiments
Any results in abstracted setups have to be gauged against how well they can be applied
to “reality”, in our case clinically relevant configurations. Since the most realistic setup
available at present are in vivo experiments, the question arises if results from in vivo
and ex vivo experiments are comparable. Therefore we checked, whenever possible, for
differences between the outcome of both experiment types.
7.2.2 Comparison to other LEAP Evaluations
Theory [47] and previous experiments [45] predicted and showed high energy gains of
LEAP compared to single pulse defibrillation. Since the ex vivo experiments performed
so far were only done on smaller hearts or on heart preparations, an open question
remains whether these results can be transferred to larger systems. We reproduced the
experimental setup of previous studies in large parts so that differing outcomes would
probably be due to reasons inherent to the samples.
7.2.3 Frequency Dependency of LEAP Success
There is no clear consensus yet at which frequencies LEAP works best. Since it takes
several defibrillation attempts to measure the efficacy of a given defibrillation parameter
set, scanning the pacing frequency at several energies is only feasible in setups where
many defibrillation episodes can take place in a short time. Perfusion systems have a
clear advantage compared to a in vivo setup here (see also 7.1.2).
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Figure 7.1: Outline schematic of the perfusion experiment setup.
With graphics from http://www.openclipart.org.
7.3 The Experimental Setup
We set up the ex vivo experiments based on previously described configurations concern-
ing the perfusion, the optical mapping of electrical activity and electric field geometry
[94, 105].
Figure 7.1 shows an overview over our experimental setup. We perfused the isolated
heart with a warm physiological buffer solution in a transparent glass bath. The bath was
fitted with electrodes for measuring the ECG and with antifibrillation pacing panels. The
heart was stained with a voltage sensitive dye, illuminated at the excitation wavelength
and cameras recorded the optical activation signal through emission wavelength filters.
Further details about the setup are given in the following sections.
7.3.1 The Langendorff Perfusion System
Like any organ, the heart needs a sufficient supply of oxygen, nutrients and a physiologi-
cal level of ion concentrations (most prominently Na+, Ca+2 , K+) in order to maintain all
necessary physiological functions. We perfused the heart with a Krebs-Henseleit/Tyrode
solution bubbled with carbogen (95%O2 and 5%CO2). The heart itself was suspended
less than 10 cm from a bubble trap and pressure regulation block (Harvard Apparatus,
USA) in the Krebs-Henseleit/Tyrode solution bath. The bath was kept at a constant
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Figure 7.2: The general setup of the ex vivo perfusion experiment. Centered: the
glass bath in which the heart is suspended during the experiment. Above: The aortic
block, consisting mainly of a cylindrical bubble trap (cf. figure 7.1) which also reduces
pressure variation from the pump (not on the image) and a pressure regulator (to the
right). The LEDs around the bath excite the fluorescent voltage sensitive dye.
Figure 7.3: The principle of Langendorff perfusion: The per-
fusion is connected to the aorta, its pressure closes the aortic
valve (bottom) to the left ventricle (gray area). Therefore, the
perfusion solution flows completely into the coronary arteries,
keeping the cardiac muscle alive.
temperature of 36 to 37 ◦C (slightly below the physiological temperature of 37 to 39 ◦C
[106]), by actively compensating heat losses of the bath and by pre-heating the per-
fusate. We adjusted the perfusion pressure to approximately 100mmHg (13 kPa [106],
a physiological value for awake and anesthetized swine) at flow rates of approximately
300 mlmin .
In the Langendorff perfusion, which we used for all whole-heart experiments, the per-
fusing system is connected retrogradely to the aorta (figure 7.3). Since the aortic valve
is still functional, the perfusate flows mainly into the coronary arteries and supplies
the cardiac muscle with oxygen. The perfusion system also served as a pathway for
administering drugs to the heart as necessary.
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7.3.2 Optical Mapping
As described in more detail above (section 4.6.1.1), we stained the hearts with 1 to
2ml (10 µm) of voltage sensitive dye di-4-ANEPPS1. In order to obtain a sufficiently
high optical intensity, we illuminated the heart with 12 (for the pig heart) or 20 (dog)
high power green LEDs (pig: 3W, dog: up to 5W per LED, peak wavelength 530 nm,
Luxeon2). The pig hearts were suspended in an octagonal custom-built glass water
bath with 23 cm diameter. Through up to four sides of this bath, we recorded the elec-
trical activity with electron multiplication CCD (EMCCD) cameras (Cascade 128+3)
at native frame rates of up to 500Hz. The cameras were fitted with long pass filters
(cutoff edge at 590 nm)4 to maximize the intensity changes of the stained tissue. Dur-
ing the experiment, the heart was immobilized by the excitation-contraction decoupler
blebbistatin to prevent motion artifacts in the signal traces of single camera pixels.
The cameras were controlled and the images were recorded with a custom-written pro-
gram, MultiRecorder5. Additionally to recording the movies, this program allowed to
show the image signal and time traces from selected image regions. This gave us the
possibility to monitor in near real-time if the defibrillation was successful and if pacing
had any effect at all. Furthermore the power spectrum of the trace(s) was automatically
calculated, showing the dominant fibrillation frequency which was then used by us to
calculate the LEAP frequency.
7.3.3 The Electrical Configuration
During the ex vivo experiments, we used a monophasic action-potential (MAP) catheter
inside the RV to record an action potential signal from the RV apical region. This
catheter could also be used for stimulation of the heart and, in those cases where it was
the ICD catheter which was used in vivo previously, as a shock electrode.
Additionally, we placed two stainless steel needle electrodes on the sides of the bath.
Being only influenced by the heart activation’s electrical far field, their potential differ-
ence was equivalent to classical ECG signals, which provided us with an alternative way
to determine the fibrillation frequency.
The configuration of the shock electrodes was chosen in each experiment according to
the particular heart preparation:
1Life Technologies, Darmstadt, Germany
2Philips Lumileds, San Jose, CA, USA
3Photometrics, Tucson, AZ, USA
4Edmund Optics, Karlsruhe, Germany
5Main author: Johannes Schröder-Schetelig
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Figure 7.4: Top view of the perfusion bath in the pig setup. Two stainless steel plates
serve as defibrillation shock electrodes (left and right). Two needle electrodes, arranged
perpendicularly in order to minimize the voltage at the amplification module, sense
the heart’s electric far-field in the manner of ECG electrodes. This electric sensing is
supported by an MAP electrode in the right ventricle which also works as a stimulation
pacing site.
Wedge Preparations For the wedge preparations (the first three pig heart experi-
ments), we separated the left ventricle including the interventricular septum (2012-
02-14 and 2012-05-07) or the right ventricle (2012-06-11) from the rest of the heart.
In the case of LV preparations, we cut along the septum from the base to the apex
to place the ventricle in a flat manner into the bath, similar to the individual RV
preparation. The preparations were perfused through tubing leading directly into
the main arteries. For the wedge preparations we did not use the octagonal bath
but a flat container with heatable double walls. On two opposite sides of the tissue,
we set up small (2 cm2 × 4 cm2) mesh electrodes for far-field pacing.
Intact Pig Heart The shock electrodes for the whole pig heart consisted of 3 cm× 4 cm
stainless steel plates fixed at opposite sides of the water bath (figure 7.4).
Intact Dog Heart For the dog hearts, we generally used the same electrode configu-
ration as during the in vivo experiment before, i.e. patch electrodes on the epi-
cardium.
In all cases, the shock electrodes were connected via a safety switch to the defibrillator
devices we used, either one or more power amplifiers or the custom-built experimental
capacitor-discharging defibrillator.
We used the same LabView software as in vivo for controlling the defibrillator devices.
Likewise the electrical signals were amplified and digitized with Biopac modules and
recorded with the Acqknowledge recording software. The defibrillation control software
also synchronized all up to four cameras with the defibrillation attempt to enable later
analysis of the videos.
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Figure 7.5: Impedances of in vivo and ex
vivo (only whole heart) experiments. The
impedance means are pairwise significantly
different between all setups (p < 0.01) ex-
cept between the ex vivo values for pigs
and dogs, respectively. The low ex vivo
impedances meant that high currents were
required in order to deliver the necessary























































in vivo ex vivo (wedge preparation) ex vivo (whole heart)
Pig 65.8± 7.2 22.3± 2.5 7.7± 1.7
Dog 93± 14 — 11.8± 4.1
Table 7.1: In vivo and ex vivo impedances compared. Impedance (mean ± standard
deviation) given in W.
7.3.4 Effective Energy Transfer
Maybe the most important physical difference between the in vivo and ex vivo setup is
not the heart itself but its environment. In contrast to the complex mixture of bone,
muscles, air (in the lungs) and other tissue, the specific conductivity of the perfusion solu-
tion in the bath is comparatively low. The impedance for all in vivo experiments ranged
from 54 to 106 W, whereas the ex vivo experiments (intact heart only) had impedances
in the range of 5.6 to 17 W (see table 7.1 and figure 7.5 for mean values and standard
deviation).
Especially in the pig heart experiments, it remains an open question how much of the
current actually flows through the heart instead of around it and through the Tyrode
solution. The heart’s cross-sectional area was about one third as large as the bath’s area
and the cardiac muscle conductivity (about 0.5 Sm and even lower if transverse to the
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fiber orientation [107]) is much lower than the conductivity of an approximately isotonic
saline solution (1.4 Sm [107]). This meant that, as opposed to the setup in the in vivo
experiments, most of the current would not flow through the heart, which increases the
total power necessary for defibrillation. The electrical configuration posed no problem
for the dog heart experiments where we had the mesh electrodes placed directly on the
heart’s surface. In this setuup, more of the delivered energy was able to activate the
cardiac tissue and thus terminate fibrillation.
In the pig heart experiments, we performed some defibrillation attempts with our ca-
pacitor discharging experimental defibrillator. Two times during these experiments, the
capacitor current was too large (at or above 60A) and some electronic parts were dam-
aged, although lower voltages or currents failed to defibrillate the heart. When using the
power amplifiers, we sometimes had to increase the duration of the pulses considerably
in order to defibrillate with single shocks.
7.4 Experimental Procedure
We performed successful ex vivo LEAP experiments on 11 pig and 6 dog hearts. All
hearts were excised from animals after they were sacrificed after the end of in vivo ex-
periments which were performed according to the local animal welfare regulations (ap-
provals by Niedersächsisches Landesamt für Verbraucherschutz und Lebensmittelsicher-
heit (LAVES) for the pig experiments and Institutional Animal Care and Use Committee
(IACUC) at Cornell University for the dogs). Most of these preceding experiments were
LEAP experiments we conducted ourselves (see the previous chapter for more informa-
tion), and some pigs were used before in non-cardiac related experiments [108] of the
OMS department6 at the University Medical Center Göttingen. The following table
gives an overview over the number and origins of the examined animal hearts for all
successful ex vivo experiments.
animal origin number of hearts
Pig (German Landrace, juvenile) LEAP experiment 1
Pig (Göttingen Minipig, adult)
LEAP experiment 2
OMS experiment 8
Dog (Beagle) LEAP experiment 6
6Oral and maxillofacial surgery (Abteilung Mund-, Kiefer- und Gesichtschirurgie an der Univer-




Prior to excision of the heart, the animal was given heparin and cardioplegic (with a
high Ka+ concentration) solution to prevent blood coagulation, to arrest the heart in
the diastolic state and to protect it during the following period of reduced metabolism
[109]. Immediately after the heart was taken out of the chest, it was put into a container
with more ice-cold cardioplegia solution until further preparation.
The cardioplegia solution had the following molar concentrations:









Before connecting the heart to the perfusion system, it was cut clean of tissue that was
not functionally essential, such as fatty or connective tissue and unneeded arteries or
veins. This way, the myocardium would be optimally visible for the camera during the
experiment.
Already during the in vivo part of the experiment, the water bath and the perfusion
solution were heated to 37 ◦C. After preparing the heart, we connected it to the perfusion
system, taking care that no air was left inside the heart or the tubing system. Once
inside the bath, we put the MAP electrode into the heart’s RV, connected the ECG
electrodes and shocking electrodes and let the heart come “back to life” for at least
30 minutes. During this time we started to add blebbistatin to the perfusate (about
7 µmol) in order to reduce optical motion artifacts from muscle contraction. Shortly
before the start of the experiment, the voltage sensitive dye di-4-ANEPPS was added
(10 to 20 nmol).
7.4.2 Simulating a Physiological Environment
During the experiment, we kept the heart as close to physiological levels as possible in
all relevant parameters. The temperature of the bath and the perfusate was regulated
to 37 ◦C and the perfusate was continuously bubbled with oxygen and carbon dioxide.
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Table 7.3: Compositions of the solutions used in the Langendorff perfusion experi-
ments. For the pig hearts we used the Krebs-Henseleit, for the dogs Tyrode’s solution.




























Figure 7.6: Experiment durations and number of defibrillation events for the ex vivo
experiments. Times measured from the first to the last defibrillation episode. Compare
also to figure 6.13.
Physiological ion concentrations and a sufficient level of glucose were maintained through
perfusion with Krebs-Henseleit solution (for the pig hearts) and Tyrode’s solution (for
the dog hearts). The respective component concentrations are given in table 7.3.
During the first ex vivo experiments on dog hearts, unfortunately we did not have a
sufficiently big bubble trap at our disposal, so that a few dog hearts suffered from air
embolization and the experiment had to be aborted. After we exchanged the bubble
trap however, we were able to keep the heart in a healthy state, cf. figure 7.6.
7.4.3 Defibrillation Energies
Exactly as in the in vivo experiments, ventricular fibrillation (VF) was induced by low-
field (about 0.5 to 2 Vcm), high-frequency (about 50Hz) pulse trains. These pulses were
delivered via either the MAP/catheter electrode or the shock electrodes.
Similarly to the in vivo experiments, we tested the necessary defibrillation energies for
LEAP in comparison to the energy values for single shocks. As in [45], we set the total
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pulse length of the biphasic pulses to 8ms whenever possible. We evaluated the defibril-
lation threshold (DFT) by attempting to defibrillate with varying shock energies around
the suspected threshold. We repeated the DFT measurement several times during each
experiment in order to detect possible drifts and changes in the responsiveness of the
heart. While this is a reproduction of the procedure in the in vivo experiments, there is
one major difference: If a defibrillation attempt turned out to be unsuccessful, we could
simply continue with the next try without delivering a backup shock and waiting for the
heart to recover, since the heart was not in danger of ischemia.
We set up the configuration for most of the LEAP shocks as described in [45]: Five
rectangular biphasic pulses with a total duration of 8ms. The pacing frequency f
was chosen either 10 to 20% above or below the dominant fibrillation frequency f as
determined from live power spectra (obtained by Fast Fourier Transform, FFT) of the
heart’s electrical activity. We varied some of these settings, such as the frequency ratio,
in order to find the lowest necessary energy.
In the experiments on pig hearts, the shock electrode configuration was as described
above in section 7.3.3 except for two days (2012-06-25 and 2012-06-28) when we used
one external electrode and an intraventricular catheter as in the in vivo experiments.
In the dog heart experiments, we varied the electrical setup in order to reproduce the
varying in vivo experiments and to find the electrode configuration which would minimize
the required energy for the following open chest experiments. For example, we tested the
feasibility of glued electrodes ex vivo first before putting this technique into practice in
vivo. Towards the end of the dog experiments, we also switched from separated phases
of LEAP and DFT measurements to an interleaved pattern: After each three attempts
to terminate VF with LEAP, we inserted one attempt to defibrillate with a single shock,
at an energy above or below the previous unsuccessful or successful single shock energy.
This DFT measurement pattern allowed us to quickly detect whenever the fibrillation
would become more or less vulnerable to shocks.
For some electrode configurations in the pig heart experiments, it was not possible to
measure the defibrillation threshold, since the impedance of the perfusion bath setup
was too low: It turned out that even at the maximum current of the 1 kW amplifier
(10A), the heart could not be defibrillated, neither at the usual pulse widths of 8 to
10ms nor at longer pulses of up to 70ms. Therefore for those experiments, it only makes
sense to compare the LEAP thresholds to the lower limit of single pulse DFT defined
by said long single pulse energy values.
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7.4.4 Frequency Scans
In order to solve the question about which pacing frequency is most beneficial for LEAP
success, we systematically varied the pacing frequency f and evaluated the defibrilla-
tion success rate for the respective frequency.
After estimating the DFT energy Ê, we chose a considerably lower energy E1 < Ê for
which we still expected some measurable success with LEAP, typically at about 40%
of Ê. We attempted to terminate fibrillation with E1 at several pacing frequencies f
at and around the dominant fibrillation frequency f . We varied the frequency ratio
f /f around 1 in steps of 0.1 or 0.05 in both directions until the success rate dropped
to near zero. For each of these frequency ratio values, we estimated the success rate
by performing three defibrillation attempts. At the latest after the frequency scan, we
measured the DFT again, and if it did not change much, repeated the frequency scan for
another energy E2, higher or lower than E1 depending on whether the range of successful
frequencies was already very narrow or not.
7.5 End of Experiment
As in the in vivo experiments, the experiment continued as long as the heart was in a
physiologically stable state. If the efficiency of the dye decreased due to bleaching or
if the heart started contracting again, we administered another dose of di-4-ANEPPS
or blebbistatin, respectively. Regular monitoring of the DFT gives early evidence of
unwanted DFT drift which may distort the perceived energy gain by LEAP. If however
fibrillation could be terminated with too low energies, could not be induced anymore or





8.0 On DFT Measurement
The measurement of the “defibrillation threshold” (DFT) is notoriously difficult and a
topic of many debates [110]. It is routinely estimated for freshly implanted ICDs [111]
in order to configure their defibrillation energy, although there are discussions whether
this actually is the best practice or if other methods are better suited to customize ICDs
(Swerdlow et al. give an overview over ICD calibration methods in [112]).
A common misunderstanding is the perception that the DFT be a fixed property which
can be measured with a certain degree of confidence. At the basis of these difficulties
lies the probabilistic nature of defibrillation. There is no fixed energy (or electric field
or current density, for that matter) below which fibrillation is never terminated and
above which defibrillation always succeeds, i.e. no threshold as such. On the contrary,
the efficacy of defibrillation is best represented by a dose-response curve, with zero
success probability at low energies and an increasing probability for higher amplitudes.
The energy with 50% success rate E50 is typically about 10 J for ICDs and the width
between the 20 and 80% energies is estimated to be E80 − E20 ≈ 0.6E50 [111].
For the application of adjusting the ICD energy the exact dose-response curve is of minor
interest. In clinical application settings, it is sufficient to be certain that the set ICD
defibrillation energy is high enough to defibrillate in nearly all cases. Exact details of
the measurement method notwithstanding, the principle of choosing the ICD energy is
always the same. Assume there is a way to get a measured DFT EDFT, which with a high
probability (e.g. 95%) is at most some chosen energy lower than E99. Then increasing
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the DFT by a so-called measured safety margin EM should result in an energy EICD
which is an (unknown but positive) intrinsic safety margin above the required E99.1
The DFT is not defined as a specific feature of e.g. the dose-response curve. Contrariwise,
its definition follows purely from a specific measurement protocol, with the objective to
keep the variance of EICD as low as possible while minimizing potential negative side
effects of the measurement on the subject. Among the most popular protocols are (more
details in [114]):
Step-Down (alternatively: Step-Up) Start with an expected successful (unsuccess-
ful) energy and decrease (increase) the energy by fixed amounts until defibrillation
fails (succeeds) for the first time. The last (finally) working energy is EDFT. This
method’s lower confidence interval limit can be improved by finding the lowest
energy for which defibrillation worked twice or three times in a row (then the
method is called DFT+ or DFT++), and the initial up/down direction could also
be chosen upon the outcome of the first defibrillation attempt.
Binary Search If the distribution of expected dose-response curves is known, it may
make sense to search for the DFT by interval bisection. Starting at the average
E50, the energy is increased or decreased in successively smaller steps depending
on the previous defibrillation outcomes.
These protocols claim to find a realistic DFT within typically 3 to 4 (for the binary
search) defibrillation attempts or fibrillation episodes. While the results may be sufficient
in order to determine a safe EICD, the error margin is still too large for quantitative
comparisons of single pulse and LEAP energies, unless one performs a prohibitively
large number of defibrillation attempts, and the outcome may depend on factors like the
energy step between tries (see the infobox “Manipulating the DFT”).
In our experiments, we typically followed a modified step up/down method: If defibril-
lation succeeded at one energy, we decreased the energy, else we increased it for the next
attempt. Without immediately resulting in a single energy value, this method is guar-
anteed to have the majority of its direction changes around E50. Examining “unequal
pairs” of successful and unsuccessful defibrillation attempts therefore allows to directly
compare two different defibrillation methods, single pulse and LEAP in the examined
case. The Unequal-Pairs method and other approaches to determining defibrillation
efficacy are presented in more detail in the appendix, section A.2.
1Terminology in italics taken from Barold et al. [113] and from Singer and Lang [111].
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The sensitivity of the DFT on the measurement protocol
As an example of how the DFT outcome can depend on the choice of protocol parameters,
let us consider the commonly used step down method. Starting with E0, the energy is
reduced by ∆E until defibrillation fails at Ek. Ek−1 is then considered to be the DFT.
E0 is usually chosen so that the success probability Pr(E0) ≈ 1, and with a probability
of p%, the DFT will be larger than E100−p. For a “wisely chosen” E0 and ∆E, the DFT
will be probably close to E50, so as to minimize both the risk of delivering too small
shocks in case of fibrillation but also the delivered energy. This choice of E0 and ∆E
depends on prior knowledge of the dose-response curve of course though and also imposes
a limit on the accuracy of the DFT result (the width of the probability distribution).
With decreasing ∆E though, the resulting DFT increases, with the limit being at E0
for ∆E → 0. This limitation remains valid even for procedures where the DFT is
confirmed by several more defibrillation attempts at the same energy. The practical
implication is that while clinical DFT estimation methods may have their application in
everyday practice to adjust ICD settings in patients, their applicability for quantitative
defibrillation efficacy needs to be thoroughly evaluated.
8.1 Results of the In Vivo Experiments
8.1.1 Evaluation of the Experimental Defibrillator Setup
We found that our in vivo setup is a valid test bed for assessing clinical defibrillation
settings. Except for a single case where the animal died due to prolonged fibrillation
episodes (pig, 2012-01-16), the animals showed physiologically stable parameters over
the course of the experiment. In all animals but one, fibrillation could be successfully
induced by fast local pacing (tip of ICD catheter, 50 to 60Hz) at low voltages. In the
experiment where this induction method failed, it turned out that the catheter tip had
become detached from the endocardium (pig, 2011-11-28).
In nearly all experimental setups, the energy and current delivered by the experimental
defibrillators were sufficient to defibrillate with a single shock. The only exception during
the pig experiments was when we tried patch electrodes on the skin in a ventral-dorsal
configuration. In this case even the commercial defibrillator we used for backup rescue
shocks failed to terminate ventricular fibrillation (2012-02-13). Similarly, at two open-
chest dog heart experiments, the power amplifiers could not deliver sufficient amounts
of current: For the tested electrode configurations, the impedance was too high for the
amplifier configuration so that only the backup shocks could finally defibrillate (2013-
03-05 and 2013-03-06).
We acquired control, bioelectrical and other physiological signals at a sampling rate of
2 kHz continuously during each experiment. For each defibrillation attempt, there exists
electrophysiological data (ECG or catheter MAP) for the seconds preceding the shocks.
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Figure 8.1: Energies of two in vivo experiments. The thin symbols represent the single
attempts’ energies, the thick symbols, connected by dashed lines, are the estimated E50
defibrillation energies by the Unequal-Pairs method (conservative).
After the shock, it took the Biopac modules typically a few seconds to recalibrate the
internal automatic gain settings.
8.1.2 Defibrillation Energies
Figure 8.1 shows the measured energies for the events of two typical experiments. The
experiment on 2012-02-07 (figure 8.1a) ran over 2 h39min, the experiment in March
2013 (figure 8.1b) lasted for nearly 214h. The small symbols in the plots show the
individual defibrillation attempts, in the order they were performed. The large triangles
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and circles are the typical defibrillation energies, estimated by the Unequal-Pairs method
as described in the previous section and in A.2. Here the more conservative approach
was used, where for single shocks the lower and for LEAP the higher energy was taken.
The dog experiment shows a behavior typical for experiments of longer duration, strong
fluctuations of the dose-response curve. While at the beginning the defibrillation thresh-
old seemed to be around 1 J, half of that value was sufficient later in the experiment to
reliably defibrillate.
The energies for all in vivo experiments and the E50 estimate are shown in figure 8.2–8.5.
The energies were in the expected range for the given electrode configurations, about
15 to 25 J for ICDs and 0.5 to 3 J for the mesh electrodes. The exact values differed
from case to case, probably due to different electrode configurations and animal age and
weight.
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8.1. Results of the In Vivo Experiments
8.1.3 LEAP Efficiency (In Vivo)
For all in vivo experiments, we calculated the mean energy 〈E 〉 required for single
pulses and the mean and minimum energies 〈E 〉 and E min which were sufficient when
pacing with 5 pulses.
These energy estimates, for the same examples as above, are shown in figure 8.6. As
in most experiments, the mean estimated energies were significantly lower for LEAP
than for single pulses. The energy gains for all in vivo experiments, 〈E 〉〈E 〉 and
E min
〈E 〉 , are
plotted in figure 8.6 and shown in the following table:








Pig, 2011-09-26 26.4 0.67 0.51 0.74 *** 3.3× 10−7
Pig, 2011-12-12 13.4 0.72 0.54 0.86 ** 0.0055
Pig, 2011-12-192 9.59 1.12 1.09 1.26 0.95
Pig, 2012-02-07 14.3 0.53 0.43 0.66 *** 0.0001
Pig, 2012-02-13 13.8 0.63 0.55 0.88 * 0.013
Pig, 2012-02-14 7.86 0.62 0.57 0.80 ** 0.0020
Pig, 2012-05-07 30.6 0.62 0.51 0.86 ** 0.009
Pig, 2012-05-14 21.7 0.60 0.45 0.84 * 0.012
Pig, 2012-05-21 27.3 0.71 0.51 0.85 ** 0.0016
Pig, 2012-06-11 18.5 0.74 0.51 0.91 ** 0.0077
Dog, 2013-03-01 0.45 0.36 0.25 0.54 *** 0.00021
Dog, 2013-03-04 0.92 0.30 0.21 0.64 ** 0.0023
Dog, 2013-03-06 2.4 0.47 0.26 0.76 * 0.019
Dog, 2013-03-07 1.2 0.56 0.53 0.63 *** 1.7× 10−7
Dog, 2013-03-08 0.55 0.38 0.30 0.53 *** 7.0× 10−6
Pig, mean(±47.5%)2 0.65(5) 0.51(3)
Dog, mean(±47.5%)2 0.41(13) 0.31(16)
Statistical significance3 in this table is denoted by one, two or three asterisks, which
stand for a p-value smaller than 0.05, 0.01 and 0.001, respectively; the 5th column shows
the upper limit of the 95% confidence interval. On average over all dog experiments,
with LEAP the energy could be reduced to 41%, with an average “best energy per
experiment” of 31%. The numbers in parentheses in the last two rows give the distance
of the mean to the limits of the 95% confidence interval.
2In the experiment of 2011-12-19, the single pulse energy increased significantly by 50% before the
first LEAP energies could be estimated. Therefore this experiment’s energy gain values were ignored for
the mean.
3In the difference of energy means, evaluated by a one-sided t-test.
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Figure 8.6: Energy estimates (conservative) of the in vivo experiments shown in
figure 8.1. Two asterisks (∗∗) denote statistical significance of means of p < 0.01, three
(∗ ∗ ∗) mean p < 0.001. Here the mean gain in the energy required for defibrillation is


































Figure 8.7: Energy gains through LEAP in all in vivo experiments with results for
both single pulse and LEAP defibrillation attempts. Mean LEAP energies (as a fraction
of the to single pulse energies) are denoted as blue circles, the minimum LEAP energies
which were found in each experiment are shown as red triangles.
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8.1.4 Frequency Dependency of LEAP Success
Due to the limited number of defibrillation events in the in vivo experiments and the
drift in the single pulse DFT, it was not possible to exactly determine the optimum
pacing frequency f in relation to the dominant fibrillation frequency f .
In figure 8.8, we pooled pooled all events from the in vivo experiments, separately for
dogs and pigs. Instead of the total energy, which varied depending on the configuration,
we normalized it by the mean of the estimated single pulse energies (ê := E〈E 〉). The ratio
of successful vs. unsuccessful attempts at such an energy and the projected frequency
ratio (f̂ := ff ) is presented through differently sized circles, the area is proportional
to this success rate. Since the average single pulse energy was not constant over the
course of an experiment (see the next section) and here f̂ only represents the frequency
ratio we targeted during the experiment, the exact number may vary for each event.
Nevertheless, this method allowed us to gain information from as many data sources as
possible.
In the pig experiments, we could not find a preference for a specific frequency ratio.
This result is in line with the frequency-success plots for each single experiment, shown
in the appendix in section B.2. The dog experiments, in contrast (figure 8.8b) indicate
a preference for frequency ratios < 1 at low to medium energies.
In the dog experiments, for those energies with at least three events on either frequency
side, the estimated average success rates Pr are:




As evaluated with a paired t-test, given these measured probabilities, with p = 95%
the success rate of overdrive pacing (f̂ > 1) is at most 5 percentage points higher than
underdrive pacing (f̂ < 1). This suggests that underdrive LEAP may indeed be more
efficient than overdrive pacing.
8.1.5 Reproducibility
The energy reduction values from section 8.1.3 (LEAP Efficiency (In Vivo)) were pos-
sibly influenced by one factor: drifting of the single pulse DFT over the course of the
experiment. In some experiments, the energy estimates did not stay nearly constant as
expected, but exhibited sudden jumps in either direction or drifted towards considerably
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(b) Dog in vivo defibrillation probabilities
Figure 8.8: Defibrillation probabilities for LEAP at different frequencies and energies.
The area of the circles corresponds to the success ratio which is also given as numbers
(success/total attempts) above the symbols. For frequency-energy configurations with-
out numbers, no data is available. Only for the dog experiments (bottom plot) there
seems to be a consistent preference for a distinct frequency range, lower pacing frequen-
cies (f < f ) in this case. For all energies of at most half the single pulse energy and
with at least three events on either side of f̂ = 1, the lower frequencies have consistently
higher success probabilities.
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higher or lower values. When this happened suddenly after a long running experiment,
we assumed the animal was in an irrecoverably pathological state and terminated the
experiment.
The most prominent examples of irregular DFT estimates, with no apparent reasons for
this behavior, are:
Experiment DFT energies Comment
Pig, 2011-10-31 rising continuously from 18.8
to 29.0 J
rise by > 50%
Pig, 2012-06-11 falling continuously from 23.7
to 13.9 J
decline by ≈ 40%
Dog, 2013-03-04 mean DFT first around 1.3 J,
later around 0.43 J
p-value after Student’s t test:
p < 0.0005
Dog, 2013-03-08 in the middle of experiment:
drop of DFT from around
0.58 J to 0.25 J and immediate
rise to the old values again
rise to “regular” values af-
ter DFT drop may have
been caused by increased rest-
ing times between fibrillation
episodes
If unexpected changes similar to these happened during LEAP attempts, they may have
biased the LEAP efficiency values without being detected.
The increased resting time between fibrillation episodes during the last two dog experi-
ments did not show conclusively that the single shock DFT would become more or less
stable over the experiment or if the resting time has any influence on the comparability
of different experiments. It allowed however to record at least as many events (2013-03-
07, n = 38) or even significantly more (2013-03-08, n = 77) compared to shorter resting
times.
We performed LEAP experiments on pigs and dogs, albeit with different electrode con-
figurations. Therefore direct comparison of achieved results is neither possible nor nec-
essary. There were no noticeable differences for the energy requirements between the
pig races we used.
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8.2 Results of the Ex Vivo Experiments
8.2.1 Setup Evaluation and Comparison to In Vivo
For pig and dog heart experiments, the ex vivo setups were designed to reproduce the
respective in vivo environment as far as possible. The impedances were significantly
lower than in vivo though (c.f. table 7.1), therefore we used power amplifiers for nearly all
experiments instead of our custom-built defibrillator prototype. We found that generally
the same methods for VF induction and termination could be applied in vivo and ex
vivo and yielded comparable results, both for far-field electrodes (pig) and epicardial
patches (dog).
Electrical and electrophysiological data was acquired with the same combination of soft-
ware and hardware as in vivo and with the same restrictions imposed by the automatic
calibration after shocks. Additionally we acquired fluorescence imaging movies for most
events, which do not suffer from this type of limitation and give immediate feedback for
the heart’s activation state during and after the shocks.
Owing to the low impedances and large volumes of water around the heart, for some
hearts the energy requirement for single pulses exceeded the capabilities of our power
amplifiers. Therefore on six experiments, the defibrillation energy data could not be
normalized by the respective single pulse DFT.
8.2.2 Defibrillation Energies
Using the same notation as in section 8.1.2, the energies for all ex vivo experiments are
plotted in figure 8.9 – 8.14. Depending on the configuration, the typical single pulse
energies ranged from under 0.5 J to some value above 45 J (higher than what could
be provided by the amplifiers). The necessary LEAP energies were consistently at or
below the single pulse energies, down to below 0.2 J. As expected, the in vivo and
ex vivo energies were comparable for the dog heart experiments, since the electrode
configurations were virtually identical.
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8.2. Results of the Ex Vivo Experiments
8.2.3 LEAP Efficiency (Ex Vivo)
For each experiment, we calculated the energy distributions of single pulse and LEAP
energy estimates, always averaged over a whole experiment. Figure 8.15 exemplarily
shows the energies for two experiments with comparatively many measurements. As
in the in vivo experiments, the LEAP energies were significantly lower than the single
pulse energies. Figure 8.16 shows the average and maximum gain achieved in the ex vivo
experiments.
A comparison of the LEAP energy gains is given in the following table, for those exper-
iments with successful and unsuccessful defibrillation attempts with one and five pulses.








Pig, 2012-02-14 4.28 0.41 0.17 0.72 ** 0.0072
Pig, 2012-05-07 2.02 0.64 0.33 0.79 *** 0.00011
Pig, 2012-06-11 1.30 0.37 0.21 0.48 *** 5.4× 10−7
Pig, 2012-09-11 5.79 0.61 0.52 0.93 * 0.030
Pig, 2012-09-12 10.7 0.36 0.34 0.45 *** 1.5× 10−7
Pig, 2012-12-08 9.45 0.43 0.20 0.66 *** 8.4× 10−5
Pig, 2012-12-094 26.5 0.46 0.20 0.52 *** 1.9× 10−14
Pig, 2012-12-10 19.1 0.28 0.23 0.48 *** 4.7× 10−6
Dog, 2013-03-04 1.96 0.25 0.23 0.81 * 0.023
Dog, 2013-03-07 0.744 0.46 0.36 0.56 *** 1.4× 10−7
Dog, 2013-03-08 0.534 0.52 0.39 0.61 *** 3.7× 10−11
Pig, mean(±47.5%)4 0.44(13) 0.28(11)
Dog, mean(±47.5%)4 0.41(35) 0.33(21)
The indication of statistical significance of the difference of means of single pulse and
LEAP defibrillation follows the convention of one to three asterisks for successively
smaller p-values (smaller than 0.05, 0.01 and 0.001). In all experiments, LEAP was
significantly more efficient than single pulse defibrillation, with up to 83% energy gain;
on average about 70% energy gain was possible.
The same restrictions regarding interpretation of the exact energy reduction numbers ap-
ply as for the in vivo experiments: also ex vivo the single pulse energies which were used
for normalization of the defibrillation energies showed similarly fluctuating behavior.
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Figure 8.15: Energy estimates (conservative) of two ex vivo experiments, on 2012-
05-07 and 2013-03-07. Two asterisks (∗∗) denote statistical significance of means of
p < 0.01, three (∗ ∗ ∗) mean p < 0.001. With the used conservative estimate the mean





































Figure 8.16: Energy gains through LEAP in all ex vivo experiments with results for
both single pulse and LEAP defibrillation attempts. Mean LEAP energies (as a fraction
of the single pulse energies) are denoted as blue circles, the minimum LEAP energies
which were found in each experiment are shown as red triangles.
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(b) Dog ex vivo defibrillation probabilities
Figure 8.17: Defibrillation probabilities for LEAP at different normalized frequencies
f̂ and energies ê. The area of the circles corresponds to the success ratio which is also
given as numbers (success/total attempts) above the symbols. For frequency-energy
configurations without numbers, no data is available. There is no clear bias for the dog
experiments (bottom plot), but in pig hearts (top) the evaluation shows that f < f
is clearly more promising to terminate fibrillation.
122
8 LEAP Experiment Results 8.2. Results of the Ex Vivo Experiments
8.2.4 Frequency Dependency of LEAP Success
Owing to the higher overall number of defibrillation in ex vivo experiments, more data
could be collected about LEAP at different frequency ratios. In analogy to figure 8.8 in
the in vivo results section, figure 8.17 shows the defibrillation success rates for different
energies and frequencies.
The number of successful defibrillations at lower energies in the dog experiments is
not sufficient for conclusive results regarding the optimum pacing frequencies. The
pig experiments, on the other hand, clearly show that underdrive LEAP (f < f )
yield a significantly better success rate overdrive LEAP. A t-test comparing the success
probabilities for each energy level showed that with p < 0.005 lower frequencies result
in higher defibrillation probabilities. This result confirmed the hints from the respective
in vivo analysis (section 8.1.4). The success probabilities (pig experiments) are:





8.2.5 Reliability of DFT Measurements
Some ex vivo perfusion experiments suffer from similar variability in the single pulse
DFT as in vivo experiments, complicating the interpretation of LEAP pulse energies.
Prominent examples (see the energy plots in figure 8.9 to 8.14 for the measured energies)
are:
Experiment DFT energies Comment
Pig, 2012-05-07 large variation in the single pulse DFT,
overlapping with LEAP energies
Pig, 2012-12-08 single pulse DFT varied from beyond the
amplifier’s capacity (≈ 50 J) to about 5 J.
Dog, 2013-03-08 single pulse DFT declined nearly continu-
ally from 0.8 J to 0.35 J, interrupted by a
short and sharp drop after approximately
110min after the start of the experiment.
The same heart
showed a similar
drop in vivo be-
fore.
4In one experiment (2012-12-09) the actual single pulse energy was much higher than calculated here
and beyond the technical limits of the amplifier during most parts of the experiment, certainly above





9.1 Prediction of Activation from Vessel Sizes
I found that the diameter of the coronary vasculature of the heart follows a power
law distributions, for atria (α = −2.74(5), dog) and ventricles (α = −2.75(30), dog)
and across different species, dogs and pigs (α = −3.47(76)) (chapter 5). Although the
exponent for pig hearts (the data is from the ventricles) is smaller than for dogs, this
difference is not significant given the current data. My measured data differs significantly
from the exponents which one can obtain from processing other published data by Kassab
et al. [65] (α = −1.14(25)). This deviation is likely due to the large variances in the
published data.
The size distributions from dogs and pigs are in agreement with the hypothesis that
the scaling of cardiac blood vessels is universal among different species. Yet differences
between species are possible, so for a conclusive result, further measurements, both for
pig hearts and possibly another species, are necessary in order to reliably evaluate their
vascular scaling distributions.
Another power law, regarding the time until cardiac tissue was activated after externally
applied electric fields, could be successfully linked with the size distributions. Taking
into account the dimensionality of the tissue, we used a well-understood generic model
of the behavior of excitable media to transform one power law into the other. The
predicted activation time exponents were compatible with the measured values.
This connection clearly demonstrates that cardiac structure elements in the form of
blood vessels constitute sources of wave emission. Wave emissions of this type are the
probable agents for the efficacy of arrhythmia termination via LEAP and will be the
key to understanding how arrhythmias can be terminated at low voltages.
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(a) ICD case and catheter (b) patch electrodes
Figure 9.1: Schematic comparison of different electric field geometries. Figure (a)
shows the field between the ICD case phantom on the left and the catheter electrode
inside the right ventricle of the heart. The hatched area to the right marks the region
with marginal or no electric field. (b) The electric field between two patch electrodes.
Although it is weaker in the outer regions, there are no parts of the heart with vanishing
field.
9.2 Setup Evaluation
The in vivo experimental setups provided reliable means to safely induce and termi-
nate ventricular fibrillation in the animal, in configurations corresponding to ICDs in
clinical practice and to previously published setups. The animals were typically physi-
ologically stable for 2 to 5 hours, allowing about 40 defibrillation episodes. In all cases
with sufficient oxygen supply, the heart could be used for another series of ex vivo ex-
periments, which confirmed that the heart was not damaged substantially during thein
vivo experiment.
The fact that the impedances and necessary single shock energies of the pig setup are
comparable to those in human ICD patients implies that the demonstrated energy gains
through LEAP can be expected not only in the animal model but also in human ICD
patients. Insofar as the pig and dog experiments can be compared (tables on pp. 108 and
120), it seems that patch electrodes are more beneficial for energy reduction through
application of LEAP. One reason may possibly lie in the field geometry, patch elec-
trodes prevent regions of zero electric field, compared to an intraventricular catheter
and submuscular ICD can (figure 9.1).
The ex vivo setup continued to provide an adequate environment for the excised heart,
keeping it active for several hours after initiation of the perfusion. The staining with
voltage sensitive dyes not only allows contactless measurement of activation, it also
indicates which parts of the heart are properly perfused. The energy requirements in the
dog experiments were considerably lower than in the pig experiments, enabling the use of
power amplifiers which could defibrillate the heart reliably at the common pulse widths.
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Animal in vivo ex vivo
Pig 0.51(3) 0.28(11)
Dog 0.31(16) 0.33(21)
Table 9.1: Comparison of the minimum in required energy ( E min<E > ) with LEAP in
the pig and dog heart experiments. The pig in vivo experiments were the only setup
where the ICD case-catheter configuration was used routinely. In the other three cases,
external electrodes were used.
This may be caused by the electrode placement directly on the epicardium, reducing the
current which flows around the tissue and is therefore lost for wave emission.
Comparing the maximum achievable energy gains in vivo and ex vivo (see table 9.1, data
from the previous chapter), one finds that the values in the dog experiments are nearly
identical. The ex vivo energy gains in the pig experiments reproduced the dog results,
whereas in vivo only about 50% energy gain could be obtained. This is another strong
indication that the electric field geometry may play an important role for the efficiency
of LEAP.
9.2.1 Clinical Relevance
With single pulse defibrillation energies typically between 10 and 20 J, the pig setup
quantitatively reproduces the energies of clinical ICD implants. Since also the impedances
were in the range expected for ICDs, the setup with the intraventricular catheter and
ICD case phantom seem to be a good model system for real ICD applications. The
experimental defibrillator used in these experiments is built on the same principles as
commercially available ICDs (charging of capacitors to the desired voltage, discharging
with or without polarity switching at custom-chosen times), lowering the barrier between
experimental basic research and application.
9.3 Defibrillation Energy Measurements
The most commonly used quantitative measure to compare the efficiency of defibrillation
methods is the energy delivered to the subject. Of course the actual effect on the heart
is mediated by the current [115] which on the length scale of cells flows across the
cell membranes and thereby increases the membrane potential sufficiently to initiate
an action potential. Thus the relation between the total energy as delivered by the
defibrillation device and the defibrillation efficacy depends on many factors affecting
the current density inside the cardiac tissue: geometry of heart, thorax and electrodes,
impedance through the tissue and on the electrodes’ surface, but also the waveform
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parameters of the defibrillating pulse. Nevertheless, measuring the delivered energy has
been the de facto standard for comparing defibrillation efficiency [115] and, all other
factors being constant, does not carry any serious disadvantages.
A major issue typically arises when measuring the defibrillation requirement, due to
the stochastic nature of the fibrillation and defibrillation process. The error margin
for clinical DFT measurements is, depending on the exact method, on the order of
50% the half-probability energy E50. A “single measurement” in this context typically
consists already of several fibrillation/defibrillation episodes. This means that with only
few of these measurements, a quantitative efficiency comparison of several defibrillation
methods is not possible.
9.3.1 The Unequal-Pairs Method
The Unequal-Pairs energy measurement method as described in section 8.0 (p. 100) and
in the appendix takes into account all defibrillation attempts and therefore is suitable
for initial estimation of the defibrillation energies and further confirmation or correction
of this value. Thus, it can be seen as an enhancement of the midpoint DFT measure-
ment [116] which starts with an educated guess of E50 and then continues up or down,
depending on the initial outcome, until the defibrillation success changes. If the energy
is always varied so as to provoke a defibrillation outcome change (increasing upon failure
and decreasing upon success), the Unequal-Pairs method’s energy distribution has its
maximum at E50 for many tries.
Especially in the in vivo experiments, this DFT measurement method produced consis-
tent and quick energy checks which allowed to quickly detect fluctuations in the required
energy or confirm that the energy remained stable.
It should be noted however, that the deduced defibrillation “threshold” still depends
on the protocol, although less so than other methods. Even more protocol independent
methods would be, for example, maximum likelihood estimations (MLE) of the dose
response curve. An MLE would always result in the best dose response curve, although
its error margins of course still would depend on the test energies.
9.3.2 DFT drift
The biggest obstacle for reliable measurements of energy ratios in the experiment was
the sometimes seemingly erratic behavior of the DFT.
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The literature on the behavior of DFT over the course of prolonged fibrillation and defib-
rillation experiments is inconclusive, although a number of surveys have been conducted
in this area. Babbs et al. [117] found a drop of only about 10% in the defibrillation
threshold energy during experiments of up to 8 hours duration. In contrast, Kerber
et al. [118] identified two major factors leading to a substantial decrease in the DFT:
duration of experiment (a decline in the DFT of 22% during 2 hours) and hypoxia
(30% decline if the pO2 was reduced to 40mmHg). In [119], a DFT drop of about 30
to 40% seems to take place over 90min (six DFT measurements consisting of several
defibrillation episodes each).
In contrast to these findings, in our experiments we saw sudden jumps in the DFT
which could not be adequately explained by slow drifts. Whether the ischemic periods
or other physiological factors such as the recovery duration after fibrillation episodes are
responsible and how to control the defibrillation susceptibility remains a question to be
answered in future experiments. The general DFT drifts experienced e.g. in the ex vivo
experiments on 2012-06-11 (figure 8.10) and 2013-03-08 (figure 8.14) however seem to
confirm the previous findings in [118] and [119].
9.4 Energy Reduction with LEAP
A major objective of the LEAP experiments was to compare the efficiency of LEAP
in clinically more realistic setups to previous results published in [45]. The reported
energy reduction by 90% in ex vivo ventricular fibrillation experiments suggested in
vivo verification in an animal model and possibly in man studies as the next steps.
In all experiments with a largely homogeneous field (all ex vivo and the dog in vivo
experiments), we found that the single pulse defibrillation energy could be reduced by
approximately 70% (table 9.1), independently of species or the exact electrode configu-
ration. While this reduction does not reach the energy gain from [45], it is substantial
and could be confirmed in a large number of experiments. The energy reduction in the
pig in vivo experiments only reached 50%, a result that may well have been caused by
zones of comparatively weak electric fields (see figure 9.1).
Presumably the main difference between the experimental setup used for the results
reported in [45] and our configuration was the preparation of the heart before the exper-
iment. While we used whole hearts in nearly all cases, the previous ventricular LEAP
experiments were conducted on wedge preparations of at most about 10 cm diameter.
This difference leads to a number of implications:
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• As Panfilov convincingly argued in [99], the size of the substrate may play a crucial
role in determining the complexity of the supported dynamics. Generally the
dynamic behavior of smaller media is less complex, therefore fibrillation in wedge
preparations may be easier to terminate by lower energies.
• An essentially flat portion of myocardium may provide less possibilities for reentry
than a system of two fully connected ventricles which additionally still includes
the Purkinje fiber system.
• The exact mechanism of LEAP is not fully understood yet, but one plausible
hypothesis is the unpinning of pinned excitation waves from heterogeneities. In
the wedge preparations, such an unpinned wave would hit the (comparatively
close) boundary much more easily than in an intact heart. If on the other hand,
the tissue boundaries are too far away to be hit by the spiral core immediately,
the spiral may reattach to the heterogeneity again.
9.5 Frequency Dependency of LEAP Success
The pacing frequency f of LEAP is maybe the most important adjustable parameter
to decrease the defibrillation energy. Even if there is a clear reference frequency f
describing the dominant fibrillation behavior, the choice of f is not trivial.
Since free spirals may be driven by pacing with frequencies faster than their own [120],
f > f may seem plausible at first. For pinned excitation spirals — if they play
an important role in VF — the situation is more complex though. Depending on the
orientation of the spiral relative to the electric field, the wave emitted by a LEAP
pulse from the pinning center may detach the spiral. Intuitively, many pulses at f ,
f should hit the spiral at different phases, thereby increasing the chance of hitting
the unpinning window ρuw [48]. Behrend et al. [49] showed however that for some
models, if f > f , the pulses may lock the spiral into a phase where unpinning is
impossible, whereas slower pacing frequencies may scan the phase until they finally find
the unpinning window.
One question behind the experiments was which pacing frequencies optimized the re-
quired pacing energies. Our in vivo (section 8.1.4) and ex vivo (section 8.2.4) experiments
showed a clear preference for f < f , although there was not sufficient data to obtain
a specific optimum frequency ratio.
This result suggests that the unpinning mechanism from sources close to or directly at
vortex cores plays an important role in LEAP and that successive entrainment of the




10.1 Structure and Function
We have clearly demonstrated experimentally the existence of a link between cardiac
tissue structure and susceptibility to low-energy pulses. This result is not only a con-
firmation of predictions from theory and cell culture experiments. In the bulk tissue of
healthy hearts, the cardiac vasculature provides the necessary structural heterogeneities,
but diseased hearts may also possess other structural features, such as scars, fibrotic or
remodeled tissue. The experiments suggest that the tissue response to electric stimuli
is characteristic for the embedded heterogeneities.
Therefore, our results may open the path for new diagnostic methods and individu-
ally optimized treatments which take into account patient specific characteristics. This
may lower the energy requirements of gentle defibrillation methods such as LEAP even
further.
To date, we experimentally only investigated the effects of the vasculature. Other hetero-
geneities such as fibrotic tissue and their interaction with low-energy electric stimulation
remains to be modeled theoretically and examined in experiments.
10.2 LEAP Energy
We successfully demonstrated the efficacy of LEAP for terminating otherwise fatal ven-
tricular fibrillation in a number of diverse experiments: for two species (pig and dog),
we performed LEAP on alive anesthetized animals and on isolated intact hearts in a
Langendorff perfusion setup. LEAP was effective in all tested electric field geometries:
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nearly homogeneous fields and highly diverging fields modeled after clinically relevant
defibrillation catheter settings.
In all experiments with a reasonably homogeneous electric field distribution, I showed
that termination of VF with LEAP is consistently possible with up to 70% energy
reduction, compared to the standard single pulse defibrillation. On the other hand,
substantially less energy reduction was achieved in those experiments with highly in-
homogeneous fields. I confirmed that underdrive pacing is beneficial for LEAP success,
which supports the hypothesis that a major factor for LEAP is the direct access to
vortex cores of fibrillatory activity (as outlined in [45]) and which will be of practical
importance for the further development of optimized pacing waveform.
In order to decrease the energy requirement even more and to increase the success rates
for low energies, more theoretical and numerical work about the underlying mechanisms
is required as well as refinement of the pacing protocol. The combination of different
approaches to terminate fibrillation like the unpinning of vortices (with underdrive) and
gradual synchronization of tissue (with overdrive pacing), or real-time decision systems
for the onset timing of LEAP are promising candidates for further research topics.
10.3 LEAP Experiments
For the in vivo and ex vivo LEAP trials, we built an experiment framework consisting
of a multitude of components, with minimal differences between the experiments. High-
energy defibrillation devices, recording of physiological data and customizable software
were shared between in vivo and ex vivo setups, for dog and pig experiments. Ex vivo,
the hearts were kept in physiological conditions by a mostly custom-built Langendorff
perfusion setup which allowed the additional acquirement of optical voltage mapping
signals.
The LEAP experiments provided reliable electrical and electrophysiological data for
hours, irrespective of species, electrode setup or if the experiment was in vivo or ex
vivo. We found some evidence that increased resting times between fibrillation episodes
in vivo may be beneficial for long-term stability of defibrillation energy requirements,
although for reliable results more data is required.
In order to further optimize the success rates of LEAP, a reasonable improvement would
be an automatic control framework capable of e.g. synchronization of LEAP with acti-
vation patterns [121] or automatic adjustment of pacing frequencies.
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We found significantly better LEAP energy gains for more homogeneous electric field
geometries, so an important question for the future is if and under which conditions the
clinical catheter-can configuration can be used efficiently for LEAP. A major obstacle for
the use of epicardial patch electrodes seems to be the increased perioperative mortality
as compared to intraventricular catheter electrodes [122]. Here additional research is cer-
tainly necessary in order to find the optimal electrode configuration. To further increase
the completeness of electro-optical data gathered from ex vivo experiments, endoscopic





A.1 Solution to the Bidomain Boundary Problem at Cir-
cular Boundaries
As was first pointed out by Pumir and Krinsky [47], external fields at boundaries of
an excitable medium described by the monodomain equations modify the membrane
potential as follows:
We start with the linearized (φm = φresting + φ ≈ φresting) monodomain and boundary
condition equations (4.4) and (4.5) as introduced in section 4.1.1:
∆φ− 1
λ2
φ = 0 (4.4)
n · (∇φ−E) = 0 (4.5)
In this representation, the “electrotonic space constant” λ is constructed from the intra-
and extracellular specific conductivities, the surface to volume ratio and the effective










Let E = |E| and let θ0 be the field’s angular direction. Then for a circular obstacle
(i.e. an obstacle representing a circular boundary) of radius R, (4.5) can be expressed
in polar coordinates (r, θ):
∂rφ− E cos(θ − θ0) = 0 (A.2)
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According to this representation, φ(r, θ) can be factorized into φ(r) · cos(θ − θ0). The
following expression for φ(r, θ) follows this factorization and solves (4.4) [47]:










) cos(θ − θ0) (4.6)
Here, K1 is the modified Bessel function of the second kind. Since this function de-
creases strictly monotonically for increasing r, the change in membrane potential φ(r, θ)
is largest directly on the boundary, i.e. at r = R. The normalized membrane potential
change (or depolarization) is plotted against λR in figure 4.2 in the main text.
The physically relevant question is: How does the depolarization depend on the obsta-
cle size and is it sufficient to initialize an action potential, i.e. does it reach a critical
threshold value? For this, it is sufficient to consider φλE on the boundary in the case of
θ = θ0 + π. Let R′ = Rλ , then:






≈ λER′ for R′  1
= E ·R






As Bittihn et al. [50] showed, maximum depolarization is not reached for obstacles of
infinite size, as one might expect from figure 4.2, but for boundaries with negative
curvatures or negative R. For this case of negative curvature, basically K1 replaced by
I1, the modified Bessel function of the first kind.
Boundaries with negative curvature, i.e. concave shape, correspond to regions of excitable
medium which are enclosed by purely extracellular space. One conclusion drawn in [50]
is that e.g. a circular spot of excitable medium will have its maximum depolarization at
a radius of several λ.
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A.2 Defibrillation threshold estimation
A.2.1 Maximum Likelihood Estimation of a Defibrillation Probability
The most accurate way to characterize the defibrillation dose response curve is fitting a
parametrized curve to the data. Since the dose response curve only describes probabili-
ties, the method of maximum likelihood estimation is appropriate in this case.
Consider the probability Pr that a defibrillation attempt is successful (we denote this
with the success variable s which shall become s = 1 for successful defibrillation and 0
otherwise).
Now for a given pulse energy E this probability shall be described by the probability
function Fα which is parametrized by a set of parameters α:
Pr(E) ≡ Pr(s = 1|E) = Fα(E) (A.4)
Now consider a set of measurements
X = {x1, x2, . . .} =
{
(E1, s1), (E2, s2), . . . | (Ei, si) ∈
(




E = {E1, E2, . . .} (A.6)
S = {s1, s2, . . .} (A.7)
where each measurement xi consists of an input (the energy Ei) and an outcome (the
success si). The defibrillation probability function can be deduced from the answer to
the following question: Given E, for which set of parameters α is the outcome S least
unlikely? This is equivalent to the following formulation:
Problem A.1 (MLE for defibrillation)
Find α so that Pr(S|E) =
∏
i |Fα(Ei)− si| becomes minimal.
Since Pr(S|E) can be easily calculated for any α, this maximum likelihood estimation
(MLE) problem can quickly be solved by standard numerical methods if the measure-
ments X contain sufficient information.
137
A.2. Defibrillation threshold estimation
A.2.2 Error Estimation of the Defibrillation Probability









log (|Fα(Ei)− si|) (A.8)
The inverse of the information matrix I(α̂) [123, p. 265f.] gives an estimate for the








Unfortunately the number of measurements required to keep this error low is too high
for practical use in in vivo experiments where the actual values α may drift on the
timescale of a few dozen measurements.
A.2.3 The “Unequal Pairs” Method
The “Unequal Pairs” method invented for this work analyzes pairs of measurements
in time. Consider a series X of events as defined in A.5–A.7 above. One way to gain
information about the dose response function Fα(E) is to look exclusively at those events
whose neighbor event produced a different outcome, i.e. those i where si , si+1. We
shall consider such a pair a measurement in the context of this method since we only
use this pair’s energy for further calculations. For the sake of brevity, let us define
Pr(x|E) ≡ Pr(s = x|E) for x ∈ {0, 1} (A.11)
Pr(E) ≡ Pr(1|E). (A.12)
Then the measurement probability Pr(measurement|E) ≡ PM (E) that the success of two
events differs is simply given by:
PM (E) = Pr(01 ∨ 10|E) = Pr(01|E) + Pr(10|E) = 2 Pr(10|E) = 2 Pr(E)(1− Pr(E))
(A.13)
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Figure A.1: Sketched probability functions for success and measured energies, for
an (“anti-symmetric”) Pr(E) which is anti-symmetric around E0. Note that Pr(E0) =
1
2 = PM (E0) = maxE PM (E), which holds for any strictly monotonic Pr(E) (with a
conveniently chosen E0).
This leads to the immediate conclusion concerning its derivatives:
∂EPM (E) = 2 ((1− Pr(E)) ∂E Pr(E)− Pr(E) ∂E Pr(E))
= 2 (1− 2 Pr(E)) ∂E Pr(E)
(A.14)
⇒ ∂EPM (E) = 0 for Pr(E) =
1
2 (A.15)
We see that the maximum of PM (E) has a value of 12 and is located at the energy where
Pr(E) = 12 (for strictly monotonic Pr(E)). Additionally if Pr(E) is anti-symmetric (up
to a constant shift) around a specific E0, i.e. if for E′ ≡ E −E0, Pr(−E′) = 1−Pr(E′),
then
PM (E′) = 2 Pr(E′)(1− Pr(E′)) = 2 Pr(E′) Pr(−E′) (A.16)
and therefore
PM (E′) = PM (−E′)⇒ PM is symmetric around E0. (A.17)
See also figure A.1 for an illustration of these relations.
A.2.3.1 Special Case: The Logistic Function
A common choice for Pr(E) is one of the most basic sigmoid functions, the logistic








. Apart from being straightforward to calculate,
it has the convenient property of being the solution to the following equation, thereby
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Figure A.2: Schematic of the measurement probabilities for several ∆. Note how
PM (E0, E0 + ∆) = Pr(E0) = 12 still holds for all ∆.
closely linking the shapes of PM and Pr:
PM (E) = 2σ2
d
dE Pr(E) (A.18)












If the energies of the two neighboring events are different (E and E+∆), this is reflected
on the measurement probability:
PM (E,E + ∆) = Pr(10|E,E + ∆) + Pr(01|E,E + ∆)
= Pr(E) + Pr(E + ∆)− 2 Pr(E) Pr(E + ∆)
(A.20)
If such a pair of events at E and E + ∆, ∆ > 0, is interpreted as the measurement of




2 ⇒ PM (E0, E0 + ∆) = Pr(E0) =
1
2 (A.21)
The maximum of PM (E,E+∆) however is shifted compared to ∆ = 0, again for strictly
monotonically increasing Pr(E) we obtain:
d
dEPM (E,E + ∆) =
Pr ′(E)+ Pr ′(E + ∆)− 2 Pr ′(E) Pr(E + ∆)− 2 Pr(E) Pr ′(E + ∆)
(A.22)
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using Pr(E0) = 12 :
P ′M (E0, E0 + ∆) = Pr ′(E0) + Pr ′(E0 + ∆)− 2 Pr ′(E0) Pr(E0 + ∆)− Pr ′(E0 + ∆)
= Pr ′(E0) (1− 2 Pr(E0 + ∆)) < 0
(A.23)
P ′M (E0 −∆, E0) = Pr ′(E0) (1− 2 Pr(E0 −∆)) > 0 (A.24)
This means that the maximum of PM (E,E + ∆) is located somewhere between E0 −∆
and E0, as shown schematically in figure A.2.
Therefore the interpretation of experimentally measured results with the Unequal Pairs
method must take into account the difference in energies of neighboring events, mea-






B.1 Vascular Size Distributions
B.1.1 Dog Hearts
Listed in this section are the vascular size distributions of the dog heart preparations
(ventricles and atria). The results of the corresponding power law fits are listed in
table 5.1a and 5.1b in chapter 5. These plots were first published in [45].
Dog Atria
Figure B.1: Vascular size distributions in dog atria: Preparation #1.
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Figure B.2: Vascular size distributions in dog atria: Preparation #2.
Figure B.3: Vascular size distributions in dog atria: Preparation #3.
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Figure B.4: Vascular size distributions in dog atria: Preparation #4.
Figure B.5: Vascular size distributions in dog atria: Preparation #5.
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Dog Ventricles
Figure B.6: Vascular size distributions in dog ventricles: Preparation #1.
Figure B.7: Vascular size distributions in dog ventricles: Preparation #2.
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Figure B.8: Vascular size distributions in dog ventricles: Preparation #3.
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B.1.2 Pig Hearts
Listed in this section are the vascular size distributions of the pig heart preparations
(ventricular vasculature). The resulting of the exponents α of the corresponding power
law fits are listed in section 5.1.2 in the chapter Heterogeneity Characterization Results.
Figure B.9: Vascular size distributions in porcine ventricles: Preparation #1. The
rendering has been lost.
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Figure B.10: Vascular size distributions in porcine ventricles: Preparation #2.
Figure B.11: Vascular size distributions in porcine ventricles: Preparation #3.
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Figure B.12: Vascular size distributions in porcine ventricles: Preparation #4.
Figure B.13: Vascular size distributions in porcine ventricles: Preparation #5.
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B.2 Frequency Dependency of LEAP Success
The following plots show the frequency dependency for each in vivo and ex vivo experi-
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Pig, ex vivo, 20120507
Figure B.14: LEAP Success for different pacing frequencies
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Pig, in vivo, 20120207
Figure B.15: LEAP Success for different pacing frequencies
152


















































































































































































































































































Pig, in vivo, 20120611
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